1	Title: Projecting vaccine demand and impact for emerging zoonotic pathogens
2	
3	Authors: A Lerch ¹ , QA ten Bosch ² , M L'Azou Jackson ³ , AA Bettis ⁴ , M Bernuzzi ³ , GAV
4	Murphy ⁵ , QM Tran ¹ , JH Huber ¹ , AS Siraj ¹ , GM Bron ² , M Elliott ¹ , CS Hartlage ¹ , K Koh ¹
5	K Strimbu ¹ , M Walters ¹ , TA Perkins ^{1*} , SM Moore ^{1*}
6	
7	¹ Department of Biological Sciences and Eck Institute for Global Health, University of
8	Notre Dame, Notre Dame, Indiana, USA
9	
10	² Quantitative Veterinary Epidemiology, Wageningen University and Research,
11	Wageningen, Netherlands
12	
13	³ Coalition for Epidemic Preparedness Innovations (CEPI), London, UK
14	
15	⁴ Coalition for Epidemic Preparedness Innovations (CEPI), Oslo, Norway
16	
17	⁵ Bill & Melinda Gates Foundation, Seattle, Washington, USA
18	
19	
20	*Corresponding authors:
21	T Alex Perkins, <u>taperkins@nd.edu</u>
22	Sean M Moore, <u>smoore15@nd.edu</u>
23	

24 Abstract

25

26 Despite large outbreaks in humans seeming improbable for a number of zoonotic pathogens,

- 27 several pose a concern due to their epidemiological characteristics and evolutionary potential.
- 28 To enable effective responses to these pathogens in the event that they undergo future
- 29 emergence, the Coalition for Epidemic Preparedness Innovations is advancing the development
- 30 of vaccines for several pathogens prioritized by the World Health Organization. A major
- 31 challenge in this pursuit is anticipating demand for a vaccine stockpile to support outbreak
- 32 response. We developed a modeling framework for outbreak response for emerging zoonoses
- 33 under three reactive vaccination strategies. Annual vaccine regimen requirements for a
- 34 population-wide strategy ranged from >670,000 (95% prediction interval: 0-3,630,000) regimens
- 35 for Lassa virus to 1,190,000 (95% PrI: 0-8,480,000) regimens for Rift Valley fever virus, while
- the regimens required for ring vaccination or targeting healthcare workers (HCWs) were several
- orders of magnitude lower (between 1/25 and 1/700) than those required by a population-wide
- 38 strategy. For each pathogen and vaccination strategy, reactive vaccination typically prevented
- fewer than 10% of cases, because of their presently low R_0 values. Targeting HCWs had a
- 40 higher per-regimen impact than population-wide vaccination. Our framework provides a flexible
- 41 methodology for estimating vaccine stockpile needs and the geographic distribution of demand
- 42 under a range of outbreak response scenarios.
- 43

44 Introduction

- 45 Less than two years ago, SARS-CoV-2 was an unknown virus circulating in a zoonotic reservoir
- 46 (Andersen et al. 2020). In the time since, it has caused a pandemic resulting in more than 4.6
- 47 million deaths (WHO 2020). Theoretical work (Antia et al. 2003) predicts that frequent small-
- 48 scale outbreaks in humans may provide opportunities for selection of more transmissible
- 49 variants that facilitate emergence from the original reservoir. Indeed, virological studies indicate
- 50 that a sequence of mutations acquired in this manner may offer a plausible explanation for the
- 51 emergence of SARS-CoV in 2003 (Sheahan et al. 2008). More frequent spillover and more
- 52 human-to-human transmission ensuing from those spillovers are expected to increase the
- 53 probability that adaptations such as these arise and facilitate more widespread emergence
- 54 (Morse et al. 2012). Because of this evolutionary potential, even zoonotic pathogens with limited
- by a basic reproduction number, R_0 , below 1—are
- 56 viewed as a concern. The status quo of investing in the development of diagnostics,
- 57 therapeutics, and vaccines only in reaction to emerging disease threats has made the world
- 58 dangerously vulnerable to pandemics (Røttingen et al. 2017; Excler et al. 2021).
- 59 To preempt future public health emergencies arising from emerging zoonotic diseases, the
- 60 World Health Organization (WHO) developed a research and development blueprint for action
- 61 to prevent epidemics (WHO 2016). This R&D Blueprint prioritizes and regularly updates a list of
- 62 pathogens for development of diagnostics, therapeutics, and vaccines
- 63 (https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-
- 64 emergency-contexts). The Coalition for Epidemic Preparedness Innovations (CEPI) was
- 65 launched in 2017 to accelerate the development of vaccines against emerging infectious
- 66 diseases and to enable equitable access to these vaccines for people during outbreaks

67 (Gouglas et al. 2019; Bernasconi et al. 2020; Huneycutt et al. 2020). The first call for proposals

68 from CEPI was on developing vaccines for Lassa virus (LASV), MERS coronavirus (MERS-

- 69 CoV), and Nipah virus (NiV). Soon after, it added Rift Valley fever virus (RVFV) and
- chikungunya virus (CHIKV) to its portfolio. As of early 2021, CEPI was supporting development
- of a total of 19 different vaccine candidates for these five diseases, in addition to other efforts
- related to Ebola, COVID-19, and "disease X" (CEPI 2018).

73 In anticipation of vaccine candidates for these diseases progressing through safety and efficacy

- trials and towards implementation, there is a need to understand future potential vaccine
- demand (Røttingen et al. 2017). Even though these vaccines are not yet available for public
- health use, understanding demand at an early stage is important to inform fundraising and
- planning efforts in support of the manufacturing and distribution infrastructure that will be
- 78 required for their implementation (Excler et al. 2021). Following the development of a new
- vaccine, manufacturing capacities are typically the first limiting factor for vaccine supply, which
- 80 raises allocation and prioritization decisions to protect people at higher risk of infection and
- 81 clinical disease (Medlock and Galvani 2009; Bubar et al. 2021). Appropriate planning of vaccine
- stockpiles to support vaccine demand is important to minimize the extent to which difficult
 decisions about vaccine prioritization must be made once a vaccine becomes available for use.
- 84 At the same time, overestimating vaccine stockpile needs could result in doses expiring and
- At the same time, overestimating vaccine stockpile needs could result in doses expiring a
- 85 resources that could have gone to other needs being wasted.
- 86 To improve capabilities to plan vaccine stockpiles for emerging zoonotic pathogens, we
- 87 developed a modeling framework to quantify the vaccine stockpile size needed to meet demand
- for outbreak response and applied it to LASV, MERS-CoV, NiV, and RVFV (Figure 1). Each of
- 89 these pathogens is zoonotic, with the majority of human cases believed to result from spillover
- 90 transmission from non-human hosts accompanied by self-limiting, human-to-human
- 91 transmission (Linthicum, Britch, and Anyamba 2016; Cauchemez et al. 2016; Siddle et al. 2018;
- 92 Nikolay, Salje, Hossain, Khan, Sazzad, Rahman, Daszak, Ströher, Pulliam, Kilpatrick, Nichol, et
- al. 2019). Our model is driven by geographically and seasonally realistic patterns of spillover for
- each pathogen, with each spillover event having the potential to spark an outbreak that we
- simulated stochastically with a branching process model. Outbreak response with reactive
 vaccination was triggered in our model whenever a threshold number of cases was exceeded
- 97 within a certain space-time window. We quantified the number of vaccine regimens required
- 98 (where the number of regimens equals the number of individuals vaccinated) under three
- 99 different approaches to reactive vaccination: 1) population-wide within the same geographic
- area as the outbreak, 2) targeted on healthcare workers (HCWs) within that area, or 3) targeted
- 101 on a ring of contacts around each index case. Using vaccines modeled after target product
- 102 profiles for each pathogen (WHO 2017c, 2017b, 2017a, 2019), we also quantified the impact of
- 103 reactive vaccination under a range of scenarios about deployment timing, coverage, per-
- 104 exposure protection (PEP) from vaccination, and several epidemiological parameters.



107 Figure 1. Overview of this study. We considered four emerging zoonoses prioritized by the WHO R&D 108 Blueprint and CEPI. For each, we modeled spillover, human-to-human transmission, and reactive 109 vaccination. We quantified the vaccine stockpile necessary to meet demands of reactive vaccination 110 under three scenarios: vaccinating an entire population within the same geographic area as a detected 111 outbreak, vaccinating healthcare workers within that geographic area, or vaccinating contacts associated 112 with each spillover case. Lassa fever is caused by LASV, a virus that circulates in rodents in West Africa 113 and has resulted in thousands of cases and deaths in recent years (Mylne et al. 2015; Roberts 2018). 114 Nipah is caused by NiV, a virus that circulates in fruit bats that can be found throughout tropical and 115 subtropical Asia (Yob et al. 2001; Luby et al. 2009), but documented spillover to humans has been mainly 116 limited to India, Bangladesh, and Malaysia (Pulliam et al. 2012; Girish Kumar et al. 2019; Nikolay, Salje, 117 Hossain, Khan, Sazzad, Rahman, Daszak, Ströher, Pulliam, Kilpatrick, Nichol, et al. 2019). MERS is 118 caused by MERS-CoV, a coronavirus that probably originated in bats (Anthony et al. 2017), and is known 119 to circulate among domestic camel populations in the Middle East and parts of eastern and northern 120 Africa, resulting in spillover from camels to humans (Müller et al. 2015; Dudas et al. 2018; Hui et al. 121 2018). Human-to-human transmission has been reported in nosocomial settings for three of these 122 pathogens (Fisher-Hoch et al. 1995; Park et al. 2016; Nikolay, Salje, Hossain, Khan, Sazzad, Rahman, 123 Daszak, Ströher, Pulliam, Kilpatrick, Nichol, et al. 2019), although only MERS was reported in large 124 hospital outbreaks (Assiri, McGeer, et al. 2013; Park et al. 2016). The evidence for community 125 transmission of these viruses is more limited (Siddle et al. 2018; Hui et al. 2018; Nikolay, Salje, Hossain, 126 Khan, Sazzad, Rahman, Daszak, Ströher, Pulliam, Kilpatrick, Nichol, et al. 2019). Rift Valley fever is 127 caused by RVFV, a mosquito-transmitted virus infecting ruminant livestock species in Africa, the Arabian 128 Peninsula, and the Indian Ocean islands (Pepin et al. 2010; Bron et al. 2021; Gerken et al. 2021). RVF 129 outbreaks have been associated with heavy rainfall in eastern and southern Africa (Anyamba et al. 2009, 130 2010), but transmission can also occur outside of these epizootic events (Linthicum, Britch, and Anyamba 131 2016). Humans can be infected via direct contact with infected animals or via mosquito bite, but are 132 believed to be dead-end hosts (Al-Hamdan et al. 2015).

- 133
- 134

135 Methods

136

137 Epidemiological data

138

139 For each of the pathogens, we collated epidemiological data through the end of 2020 from

140 multiple sources, including WHO outbreak reports (e.g., (CSR n.d.)), ProMED reports

141 (https://promedmail.org), country-level reports (<u>https://www.moh.gov.sa</u>, <u>https://ncdc.gov.ng</u>),

and a literature search. A detailed overview of the source of epidemiological data for each

143 pathogen can be found in the Supplementary Table S1.

- 144
- 145 Spillover simulation

146 Given extensive spatial heterogeneity of incidence, we collated epidemiological data at the first

administrative level (adm1) in each country—e.g., province or state—within the study region for

- each pathogen. The primary epidemiological data used to inform spillover rates was the annual
- 149 incidence of reported cases of each pathogen at the adm1 level (Table S1). Where possible,
- 150 case data was categorized into cases of documented or suspected human-to-human
- transmission, documented or suspected spillover cases, and cases of unknown origin. The

152 geographic coverage of our analysis for each pathogen was determined by the geographic

distribution of spillover cases in the literature. All countries with at least one documented

- spillover case were included in our analysis. We excluded countries with imported cases but no
- spillover from a zoonotic source (e.g., South Korea for MERS-CoV).

156 Spillover rates were estimated using a generalized linear mixed model (GLMM) with a zero-

157 inflated negative binomial distribution to capture overdispersion in the annual distribution of

spillover cases within an adm1. Spillover cases were defined as documented spillover cases,

- 159 suspected spillover cases, or cases of unknown origin; thereby excluding any cases of
- documented or suspected human-to-human transmission. Year, country, and adm1 were
 treated as random effects, with the adm1 variable nested within the country variable. Year was
- also included as a random effect for the zero-inflated portion of the model. Model fitting was
- 163 conducted using the glmmTMB package in R (Brooks et al. 2017). This default model did not
- 164 converge for NiV; therefore, for NiV we used the GLMM model without the random effect by
- 165 year in the zero-inflated portion of the model to enable convergence. Then, for each pathogen,

166 we simulated annual spillover cases for each year and adm1 by taking draws (1,000 replicates)

167 from a zero-inflated negative binomial distribution using the estimated parameters from the

appropriate GLMM fit. We randomly sampled 1,000 of these simulated spillovers from the last

169 five years as inputs to the outbreak simulation model so that the simulated spillovers would

- 170 reflect recent spillover rates.
- 171

To account for the seasonality of spillover, we fitted a beta distribution to the timing of spillover cases within a year (daily for MERS, weekly for Lassa fever, monthly for Nipah and RVF) and

174 simulated the timing of each spillover case as a random draw from that distribution (Table 1). To

175 account for spatial clustering of cases below the adm1 level, we associated each simulated

176 case with a catchment area. We did so according to probabilities proportional to catchment area

177 population. Catchment areas were defined by second administrative level (adm2) or hospitals

178 aggregated within 10 km for first administrative (adm1) areas that did not have an adm2 level. 179 These catchment areas, therefore, represent areas where individuals would be expected to 180 seek care and have their diagnosis reported, and the aggregation of hospitals within a 10km 181 area assumes that individuals who seek treatment for the relatively severe symptoms of these 182 diseases do so at larger hospitals. Hospital location data for sub-Saharan Africa used in the 183 analysis of LASV was obtained from (Maina et al. 2019), and hospital location data outside of 184 sub-Saharan Africa was obtained from https://www.healthsites.io (Saameli et al. 2018). The 185 primary set of findings we reported are based on a set of 1,570 catchment areas for LASV, 767 186 for MERS-CoV, 5,076 for NiV and 2,126 for RVFV, which differ because of the different 187 geography of each pathogen. We examined the sensitivity of our results to the definition of a 188 catchment area by rerunning the analyses with either adm1 catchment areas or all hospitals 189 within an adm1 as distinct catchment areas. The results of these analyses are presented in the 190 Supplement (SI Text).

191

192 Outbreak simulation

193

194 To simulate incidence attributable to human-to-human transmission, we considered each 195 spillover case as a potential index case for an outbreak. A schematic overview of both the 196 spillover and outbreak simulation models, including outbreak response, is provided in Figure 2. 197 Human-to-human transmission was simulated stochastically using a branching process model. 198 For each primary case, a certain number of secondary cases was drawn either from a Poisson 199 distribution (for Lassa fever and RVF) with $\lambda = R_0$, or from a negative binomial distribution (for 200 MERS and Nipah) with $\mu = R_0$ and a dispersion parameter, k. A Poisson distribution was used 201 for Lassa fever and RVF, because both have an estimated $R_0 < 0.1$ and no available estimate of 202 overdispersion. We used a negative binomial distribution for MERS and Nipah, because 203 secondary cases for these diseases are known to be overdispersed, with a majority of human-204 to-human transmission arising from a small minority of primary cases (Cauchemez et al. 2016; 205 Nikolay, Salje, Hossain, Khan, Sazzad, Rahman, Daszak, Ströher, Pulliam, Kilpatrick, and 206 Others 2019).

207



^S Model inputs that were varied as part of our sensitivity analysis

209 Figure 2. Schematic of the spillover simulation and outbreak simulation models. The spillover 210 simulation model estimates the magnitude and timing (seasonality) of the spillover rate for each 211 catchment area from the historical distribution of reported spillovers in the catchment area. These 212 estimated spillover rates are input into our outbreak model for each catchment area (as identified by the 213 bolded model input), which used a branching process model to simulate human-to-human transmission. 214 An outbreak response was triggered within a catchment area if the number of reported cases exceeded a 215 predetermined number within a 28d time window (outbreak threshold size). Outbreak model inputs with a 216 superscript S were varied as part of our sensitivity analysis. 217 218 We estimated R_0 and variability therein differently for each pathogen. For LASV, we estimated 219 an R₀ for nosocomial transmission by fitting a simple branching process model to observed 220

- outbreak sizes from (Lo lacono et al. 2015) using the optimize function in R and assuming a
 Poisson offspring distribution (Farrington, Kanaan, and Gay 2003). The resulting estimate of R₀
- for LASV was 0.063 (95% confidence interval [CI]: 0.05 0.08) (Table 1). For MERS-CoV, we
- 223 compiled estimates of R_0 from multiple studies analyzing data from MERS outbreaks
- (Cauchemez et al. 2014; Breban, Riou, and Fontanet 2013; Poletto et al. 2014; Chowell et al. 2016; Kuchemeli and Althous 2015) and departine dustrichility in these
- 225 2014; Cauchemez et al. 2016; Kucharski and Althaus 2015) and described variability in those 226 estimates with a gamma distribution, which resulted in a median R_0 of 0.583 (90% CI: 0.31 -
- 227 0.99). The dispersion parameter estimate, *k*=0.26, for MERS-CoV was obtained from (Kucharski
- and Althaus 2015). For NiV, we estimated R_0 and its variability from detailed epidemiological
- 229 investigations of Nipah outbreaks in Bangladesh that estimated person-to-person chains of NiV
- transmission (Nikolay 2019). Using data from these studies on the number of secondary

- 231 infections per primary infection and the size of each transmission cluster, we obtained
- 232 maximum-likelihood estimates of R₀ (0.33, 95% CI: 0.21 0.52) and *k* (0.048, 95% CI: 0.031 -
- 233 0.074), which were consistent with a branching process with a negative binomial offspring
- distribution. For RVFV, we assumed $R_0=0$, and considered $R_0=0.01$ for sensitivity analysis only,
- as no human-to-human transmission has been definitively documented to date (Al-Hamdan etal. 2015).
- 237 The timing of incubation and infectious periods were then simulated subsequently based on
- gamma distributions of those periods that we estimated by fitting a model to reconcile variability
- 239 in previously published estimates (Table 1). As no human-to-human transmission is known for
- RVFV, we assumed for the sensitivity analysis a fixed duration for the infectious period of 7
- 241 days that is consistent with the duration of detectable viremia after onset of symptoms (Bird et
- al. 2009). For all pathogens, the infection date of secondary cases was simulated as a draw
- from a uniform distribution over the infectious period of the primary case. Each secondary case
- was assigned to the same catchment area as the associated index case. A detailed overview of
- the source for each parameter of each pathogen can be found in the Supplementary Table S1.

Table 1. Overview of parameter estimates. Incubation period and infectious period are
 defined in units of days, and parameters for seasonality refer to week of the year. Numbers in

Parameter	LASV	MERS-CoV	NiV	RVFV
Seasonality - Peak (wk) - SD (wk)	31.1 6.2	23.3 13.6	27.3 6.4	23.2 12.7
Incubation period - Mean (d) - SD (d)	12.05 3.62	5.56 0.77	9.87 0.84	2.88 1.95
Infectious period - Mean (d) - SD (d)	11.31 8.29	13.5 2.61	6.49 0.26	7 ¹
R₀ - Mean - Dispersion	0.063 (0.05, 0.08) -	0.58 (0.31, 0.99) 1.42	0.325 (0.21, 0.52) 0.048	0 (0.01)

249 parentheses for R_0 represent the 95% confidence intervals.

250 ¹ Fixed value used for sensitivity analysis only.

251

252 Vaccine campaign simulation

253

Three different reactive vaccination strategies were evaluated: 1) vaccinating a portion of the general population in a given catchment area; 2) specifically targeting the HCWs in that catchment area; or 3) adopting a ring vaccination strategy where the local population surrounding each index case are targeted for vaccination. These strategies were chosen as they represent three of the most frequently deployed outbreak response strategies. For each

- strategy, baseline vaccination campaign parameter values (and parameter ranges for the
- 260 sensitivity analysis) were based on vaccine target product profiles for each pathogen (WHO

261 2017c, 2017b, 2017a, 2019), or chosen in consultation with CEPI and subject-matter experts for 262 each pathogen (Table 2).

263

264 To estimate the impact of vaccination, we simulated each outbreak response relative to a 265 counterfactual simulation in which there was no outbreak response. Vaccination impact was 266 defined as the number of cases averted via vaccination and calculated by taking the difference 267 between the number of cases in the vaccination and no-vaccination scenarios. In our baseline 268 scenario, an outbreak response within a single catchment area was triggered once ten cases for 269 Lassa fever and MERS or three cases for Nipah and RVF were detected within a four-week 270 window (Table 2). These outbreak response thresholds were chosen through discussion with 271 CEPI and pathogen experts, and do not necessarily match the different outbreak definitions 272 currently used by WHO or individual countries. The vaccination start date was calculated by 273 adding a delay to the outbreak response date. To simplify vaccine uptake in our model, we 274 assumed that each target population was immunized on a single day. Multi-day vaccination 275 campaigns would likely reduce the impact of outbreak response relative to our estimates, but 276 this impact would be less severe than a comparable delay in protection following vaccination 277 because at least a portion of the population would be protected at the beginning of the 278 campaign. Therefore, our analysis of the sensitivity of vaccination impact to a delay in protection 279 following vaccination could be considered an upper bound on the sensitivity to extending the 280 vaccine administration period for a given round of vaccination. In the case of a 2-dose vaccine, 281 an additional delay of 28 days was assumed between administration of the first and second 282 doses.

283

284 For the general population vaccination strategy, HCWs were treated as part of the general 285 population and were vaccinated with the same probability as the general population. For the 286 HCW vaccination strategy, non-HCWs were not vaccinated, except for a hybrid strategy tested 287 as part of our sensitivity analysis, where 20% of the general population was vaccinated versus 288 80% of HCWs (Table 2). For the ring vaccination strategy, we calculated the number of index 289 cases that would arise after the reactive vaccination campaign had started and assumed that 90 290 vaccine regimens would be needed to vaccinate a ring of individuals around each index case 291 based on estimates from ring vaccination campaigns during recent Ebola and cholera outbreaks 292 (Ali et al. 2016; Henao-Restrepo et al. 2017). For the ring vaccination strategy, we only 293 estimated the number of vaccine regimens that would be required and did not attempt to 294 estimate the impact of vaccination on cases averted, because our model was designed to 295 simulate a single vaccine campaign and not the periodic deployment as required by a ring 296 vaccination strategy.

297

Once a vaccination campaign was completed and the delay between vaccination and protective immunity had elapsed, vaccination in the general population removed spillover cases with a probability equal to vaccination coverage in the general population multiplied by per-exposure protection (PEP). Vaccination of the general population also removed patient-to-HCW nosocomial cases with probability equal to vaccination coverage in HCWs multiplied by PEP. Vaccination of HCWs had no impact on spillover cases, but it removed nosocomial cases with

whether a sufficient amount of time since vaccination had elapsed and, in the event of a twodose vaccine, whether an individual had received one dose or two doses at the time of
exposure (Table 2). Cases downstream in a transmission chain from a case averted by
vaccination were also averted.

- 309
- 310 **Table 2. Overview of simulation scenarios.** Parameter values for the baseline reactive
- 311 vaccination scenario for each pathogen. Outbreak response threshold cases and threshold
- 312 window refer to the number of cases that need to occur within a certain time window to trigger
- an outbreak response. Parameter values in parentheses are alternative values used as a part of
- 314 the sensitivity analysis.

Parameter	LASV, MERS-CoV	NiV, RVFV
Outbreak response - Threshold cases - Threshold window - Delay	10 (5) 28d 28d (7, 120)	3 (1, 5) 28d 28d (7, 120)
 Vaccination Coverage HCW¹ Coverage population Delay between dose Regimens per index case (ring vaccination only) 	70% (80 70% (20 20 9	0, 50, 90) 0, 50, 90) 8d 90
Per-exposure protection (PEP) - Single dose - Two dose 1st - Two dose 2nd - Delay	70% (50 35% (25 70% (50 7d	9%, 90%) 9%, 45%) 9%, 90%) (14)

- 315 ¹ Excluded for RVFV as no nosocomial transmission has been documented.
- 316

317 Vaccine demand calculation

318

319 To quantify the number of regimens required to meet the demands of a given outbreak

320 response strategy, we estimated the number of healthcare workers and overall population

321 associated with each catchment area where an outbreak occurred. The overall population per

322 catchment area was estimated based on WorldPop data from 2015 (Tatem 2017). For

323 healthcare workers, we took the national-level numbers of healthcare workers and distributed

324 them proportional to the population associated with each catchment area (Ref (WHO 2021)).

- 325
- 326 Graphical user interface

327

A generalized implementation of the model is provided as a graphical user interface (GUI) at <u>http://eidvaccinedemand.crc.nd.edu</u>. In the generalized implementation, a few adjustments were

330 made to allow for more flexible application of the model and to make computing time more

acceptable for an interactive web tool. First, annual spillovers are drawn from a negative

binomial distribution and then distributed across the catchment areas with a multinomial

distribution proportional to the probability that spillovers occur in these catchment areas.

334 Second, the population in the catchment areas were defined by a negative binomial distribution

so that specific geographies did not need to be reproduced. The default parameters for the GUI

of each pathogen were obtained by fitting the corresponding distribution function to the

- estimated spillover and population data from this study. The source code for the GUI is provided
- 338 at <u>https://github.com/lerch-a/CEPI_VaccineCampaignGUI</u>.
- 339
- 340 **Results**341

342 Spillover cases and human-to-human transmission

343 344 The median annual number of spillover cases was 6 (95% prediction interval: 0-190) for Nipah. 345 114 (95% Prl: 48-266) for MERS, 185 (95% Prl: 8-13,134) for RVF, and 417 (95% Prl: 142-346 1,837) for Lassa fever (Figure 3A). Simulated variability in the annual number of spillover cases 347 matched the cumulative distribution of observed spillover cases for each pathogen (SI Figures 348 S1B-S4B). Spillover rates for each pathogen varied both seasonally (SI Figures S1A-S4A) and 349 geographically (Figure 4A). Spillover cases of Lassa fever were concentrated in Sierra Leone, 350 Liberia, and Nigeria, although a few spillover cases occurred in other western African countries. 351 Spillover of RVF to humans was widespread in South Africa, Madagascar, eastern Africa and 352 the Arabian Peninsula, with frequent spillover cases occurring in several western and northern 353 Africa countries as well. The majority of MERS spillover cases occurred in Saudi Arabia, and the 354 majority of Nipah spillover cases occurred in Bangladesh, with additional spillover events in 355 India and Malaysia.

356

The number of cases arising from human-to-human transmission depended on both the spillover rate and R₀ (Figure 3A). Under our default parameter assumptions, there was no human-to-human RVFV transmission, but in the absence of vaccination the median annual number of human-to-human cases following spillover was 2 (95% PrI: 0-82) for Nipah, 29 (95% PrI: 11-143) for Lassa fever, and 161 (95% PrI: 46-407) for MERS (see Figure 5 for an example of the transmission chains for one catchment area).

- 363
- 364 Estimates of vaccine demand
- 365

366 In our analysis, a median of 0 (95% PrI: 0-8) Nipah reactive vaccination campaigns were 367 triggered annually, compared to 4 (95% PrI: 0-11) MERS campaigns, 5 (95% PrI: 0-20) RVF 368 campaigns, and 0 (95% PrI: 0-20) Lassa fever campaigns (Figure 3B). The locations of reactive 369 vaccination campaigns broadly followed the geographic distribution of spillovers for each 370 pathogen, although Lassa fever spillovers in Guinea, Benin, Togo, and western Nigeria were 371 rarely reported frequently enough to trigger a response in our simulations (Figure 4B). The number of reactive vaccination campaigns that were triggered, and the timing of those 372 373 campaigns, was strongly influenced by the seasonal pattern of pathogen spillover (SI Figures 374 S1-S4). 375







391 Figure 4. Geographic distribution of predicted spillover cases and reactive vaccination

392 campaigns. (A) Geographic distribution at the 2nd administrative level (adm2) of the expected annual
 393 number of spillover cases for each pathogen. (B) The annual probability that a campaign will be triggered
 394 in each adm2 catchment area based on 1,000 simulations.



397

Weeks since January 1

 398
 Figure 5. Timing of spillover and nosocomial cases in a single realization of one catchment area

from the MERS-CoV outbreak model. (Bottom) Individual cases are visualized as thick horizontal lines, with observed cases in yellow/orange and averted cases in gray (yellow and light gray indicate incubation time, orange and dark gray indicate infectious time). Unrelated transmission trees are separated by thin horizontal gray lines. The dashed vertical line indicates the date the outbreak threshold was reached. Triangles indicate vaccination date and diamonds indicate protection date. (Top) Number of observed (orange) and averted (gray) cases per week.

405

For all four pathogens, there was a wide range in the number of vaccine regimens required in atypical year due to the dependence of vaccine demand on the spatiotemporal clustering of

408 spillover cases required to trigger an outbreak response. The largest annual vaccine demand

409 was for RVFV, with a median of 1.191.741 (95% Prl: 0-8.480.275) vaccine regimens required to 410 target the general population under our baseline outbreak response scenario (Figure 3C). The 411 median number of vaccine regimens for MERS-CoV was 870,045 (95% Prl: 0-2,843,407). The 412 median number of vaccine regimens needed for NiV and LASV was zero, implying that an 413 outbreak response was triggered less than 50% of the time. However, the mean number of 414 vaccine regimens was 673,167 (95% Prl: 0-3,629,052) for LASV and 1,450,177 (95% Prl: 0-415 12,240,814) for NiV (Figure 3C). The number of vaccine regimens required to conduct a ring 416 vaccination strategy or to cover healthcare workers as a part of an outbreak response was 417 typically several orders of magnitude (between 1/25 and 1/700) lower than the number required 418 to cover the general population (Figure 3C). The median number of MERS-CoV vaccine 419 regimens required to cover healthcare workers was 6,786 (95% Prl: 0-22,086). A median of 420 1,540 (95% Prl: 0-62,320) vaccine regimens were needed among healthcare/veterinary workers 421 for RVFV outbreak response, 0 (mean: 1,144; 95% PrI: 0-6,485) were required for LASV, and 0 422 (mean: 2,330; 95% Prl: 0-15,833) for NiV. The median number of vaccine regimens required for 423 ring vaccination was 4,860 (95% Prl: 0-21,429) for MERS-CoV, 12,150 (95% Prl: 0-1,175,758) 424 for RVFV, 0 (mean: 13,774; 95% Prl: 0-108,056) for LASV, and 0 (mean: 2,605; 95% Prl: 0-425 21,641) for NiV.

426

427 Impact of outbreak response

428

429 The estimated impact of reactive vaccination as an outbreak response tool was generally low for 430 all four pathogens. Vaccinating 70% of the general population in response to an outbreak with a 431 single-dose vaccine prevented an annual median of 43 (95% Prl: 0-5,853) RVF cases, 6 (95% 432 Prl: 0-83) MERS cases, 0 (95% Prl: 0-90) Nipah cases, and 0 (95% Prl: 0-357) cases of Lassa 433 fever (Figure 3D). These vaccine impacts correspond to 0.69 (95% Prl: 0-2.92) cases averted 434 per 100,000 vaccine regimens administered for MERS, 3.61 (95% PrI: 0-69.02) for RVF, 0 (95% 435 PrI: 0-9.84) for Lassa fever, and 0 (95% PrI: 0-0.74) for Nipah. Vaccinating only healthcare 436 workers typically had a smaller total impact than vaccinating the general population at the same 437 coverage level, because there was no protection against spillover in the general population, but 438 a larger per-regimen impact due to the lower number of regimens required. Vaccinating 70% of 439 HCWs prevented an annual median of 4 (95% PrI: 0-77) MERS cases, corresponding to 58.9 440 (95% PrI: 0-348.6) cases averted per 100,000 vaccine regimens in HCWs. Vaccinating HCWs 441 averted 0 (95% Prl: 0-46) Lassa fever cases and 0 (95% Prl: 0-48) Nipah cases, corresponding 442 to 0 (95% Prl: 0-710.4) and (95% Prl: 0-303.5) cases averted per 100,000 HCW vaccine regimens respectively (we did not explore vaccinating HCWs against RVFV due to the lack of 443 444 any documented nosocomial transmission).

445

446 Sensitivity analysis

447

448 The number of total cases increased with higher R_0 values for each pathogen, with the largest

sensitivity observed for MERS-CoV, because its higher value of R_0 was close to one (Figure

450 S16). There was also a large increase in the number of vaccine regimens required to vaccinate

451 either the general population or HCWs for MERS-CoV at the higher R_0 value, but the impact of

452 R₀ on the required number of vaccine regimens was minimal for the other pathogens (Figures

S17-S18). As a result, there were minimal differences in the impact of vaccination under higher
or lower R₀ values for LASV, NiV, or RVFV (Figures S19-S22). Vaccination averted both a
greater magnitude and a higher fraction of MERS cases as R₀ increased (Figures S19-S20). In
addition, the number of MERS cases averted per vaccine regimen administered to the general
population or to HCWs also increased as R₀ increased (Figures S21-S22).

458

459 Lowering the outbreak threshold (from 10 to 5 cases within a 28 day window for MERS-CoV and 460 LASV, and from 3 to 1 cases for NiV and RVFV) increased both the number of vaccine 461 regimens needed for outbreak response and the number of cases averted. With the lower 462 outbreak threshold, the projected demand for MERS-CoV vaccine regimens was 2,351,059 463 (95% PrI: 492,028-5,872,847), a 170% increase, while the median number of cases averted 464 was 19 (95% Prl: 0-162), a 217% increase compared to the baseline. The required number of 465 vaccine regimens for RVFV increased to 4,793,351 (95% Prl: 659,297-14,157,197), a 302% 466 increase, while the median number of RVF cases averted was 66 (95% Prl: 0-6,066), a 53% 467 increase. The median number of vaccine regimens for LASV increased from 0 to 756,273 (95% 468 Prl: 0-6,644,995), and the median number of Lassa fever cases averted increased from 0 to 15 469 (95% PrI: 0-534). The median number of vaccine regimens for NiV increased from 0 to 470 3,501,587 (95% Prl: 0-54,814,275), but the median number of cases averted remained 0 (95% 471 PrI: 0-119). When the outbreak threshold was increased to 5 cases for RVF, the required 472 number of vaccine regimens decreased by 50% to 594,894 (95% Prl: 0-7,493,183). The number 473 of RVF cases averted via vaccination decreased to 26 (95% Prl: 0-5,735), which was 41% fewer 474 cases averted compared with an outbreak threshold of 3 cases. 475

Decreasing the time delay between the outbreak threshold being reached and the start of the vaccination campaign tended to increase the number of cases averted, while increasing the delay reduced the number of cases averted (Figure 6). For MERS-CoV, reducing the time delay from 28 to 7 days increased the median number of cases averted from 6 (95% Prl: 0-83) to 14 (95% Prl: 0-112), while increasing the delay to 120 days reduced the number of cases averted to 0 (95% Prl: 0-38).

482

483 Increasing or decreasing the percentage of the population that was targeted during reactive 484 vaccination campaigns also led to corresponding increases or decreases in the number of 485 cases averted (Figure 6). For example, if only 50%, rather than 70%, of the population was 486 vaccinated for MERS-CoV, the median number of cases averted declined from 6 (95% PrI: 0-487 83) to 4 (95% PrI: 0-72). In contrast, if vaccination coverage was increased to 90%, then 7 (95% 488 PrI: 0-93) MERS cases were averted. The number of MERS cases averted per 100,000 vaccine 489 regimens administered decreased from 0.69 (95% PrI: 0-2.92) at 70% coverage, to 0.64 (95% 490 Prl: 0-3.55) at 50% coverage, and 0.63 (95% Prl: 0-2.54) at 90% coverage. The sensitivity of the impact of outbreak response to other campaign parameters considered in our model, 491 492 including per-exposure protection, time to protection following vaccination, vaccination coverage 493 levels in HCWs, and one-dose vs. two-dose vaccines are provided in Figure 6. The sensitivity 494 analyses for the other pathogens (NiV, LASV, and RVFV) and for different catchment levels are 495 provided in the Supplement (SI Text). In general, the number of cases averted were highest 496 when the spatial scale for vaccine response (catchment area) was the first administrative level,

497 but the per-regimen vaccination impact was higher for the smaller catchment areas (second
498 administrative level or hospital-based catchment areas), because fewer vaccine regimens were
499 required per campaign in those areas (Figures S33-S34).

- 500
- 501



Figure 6. Vaccine impact sensitivity analysis for MERS-CoV. Sensitivity of vaccination
 impact for MERS-CoV to variation in different campaign parameters expressed as (A) fraction of
 cases averted, (B) cases averted per 100,000 vaccinated in the general population, and (C)
 cases averted per 1,000 health care workers (HCWs) vaccinated.

- 508 Discussion
- 509

507

510 Model performance

511

512 Our spillover simulation model estimates closely matched the average annual reported number 513 of spillover cases for each pathogen, as well as the observed interannual variability in the 514 number of spillover cases that have occurred in the past few decades. The simulation results 515 also captured the geographic distribution and seasonality of spillover cases for each pathogen. 516 The magnitude, spatial distribution, and timing of spillover rates are the main determinants of 517 how frequently an outbreak response threshold will be triggered and therefore the size of the 518 vaccine stockpile needed for outbreak response. Although these patterns could shift to some 519 degree in the future, our model represents what we know about them presently. In addition to 520 influencing stockpile size, these three factors (the magnitude, spatial distribution, and timing of 521 spillover rates) are also relevant for logistical considerations such as the geographic location(s) 522 of the stockpile and the necessary stockpile replenishment rate (Yen et al. 2015).

523

524 Stockpile estimates

525

526 The estimated number of vaccine regimens needed to reach vaccination coverage targets in the 527 general population varied considerably across the four pathogens examined. For both LASV 528 and NiV, the median was zero, indicating that reactive vaccination campaigns would not be 529 triggered more than 50% of the time. In contrast, the median numbers of vaccine regimens 530 needed for MERS-CoV and RVFV were 870,000 and 1,190,000, respectively. However, the 531 95% prediction intervals for all four pathogens were wide due to spatial and temporal 532 heterogeneity in spillover rates and overdispersion in outbreak sizes resulting from human-to-533 human transmission. For all four pathogens, the vaccine regimens needed to target HCWs were 534 several orders of magnitude lower than needed to target the general population.

535

536 These results indicate that the size of the vaccine stockpile needed to meet annual reactive 537 vaccination demands will depend on the pathogen's epidemiology, the vaccine coverage 538 strategy, and the specific demands of a sustainable manufacturing strategy. In addition to the 539 median or mean annual vaccine demand, our estimates also provide an estimate of the inter-540 annual variability in vaccine demand and the potential magnitude of vaccine demand in low-541 frequency, but high-demand years. For example, the 75th or 90th percentile of our estimates 542 correspond to the level of demand experienced once every four or ten years, on average. The 543 desired size of a vaccine stockpile will likely depend not only on the average annual vaccine 544 demand, but also on the stockpile capacity needed to adequately handle the unpredictability in 545 the timing, frequency, geography, and magnitude of outbreaks. These questions will depend on 546 sustainable vaccine manufacturing capacity, the geographic distribution of both this

547 manufacturing capacity and the stockpile, and vaccine shelf life. A graphical user interface is
548 available at http://eidvaccinedemand.crc.nd.edu to facilitate interactive exploration of these
549 dependencies.

550

551 Our vaccine demand estimates indicate that the biggest determinant of the size of the reactive 552 vaccine stockpile needs was the vaccination strategy: targeting the general population, only 553 HCWs, or ring vaccination. For pathogens that primarily cause nosocomial outbreaks (e.g., 554 LASV), vaccinating HCWs can protect high-risk individuals. In our analysis, this strategy had a 555 larger impact in terms of cases averted per vaccine regimen than vaccinating the general 556 population. The impact of vaccinating HCWs will be highest when spillovers are highly spatially 557 clustered because vaccination campaigns are more likely to be triggered in high-spillover 558 catchment areas, thereby protecting HCWs against nosocomial transmission in areas where 559 vaccination has already occurred earlier in the transmission season but where the spillover risk 560 may remain high. A ring vaccination strategy would also require significantly fewer regimens 561 than a general vaccination strategy. We estimated that the vaccine demand under a ring 562 vaccination strategy would be similar to the demand under a HCW-vaccination strategy for 563 LASV, NiV, and MERS-CoV, and moderately higher than the HCW-vaccination strategy for 564 RVFV. Another strategy to reduce the number of vaccine regimens needed per reactive 565 campaign that we did not consider in our analysis would be to target high-risk sub-populations 566 instead of the whole population of a catchment area. In the case of RVFV, this would be animal 567 workers like butchers, veterinarians, and farmers who are at highest risk of infection (Wilson et 568 al. 1994; Nyakarahuka et al. 2018; Msimang et al. 2019). For MERS-CoV, camel workers have 569 a higher risk of infection than the general population (Dudas et al. 2018). For LASV, rural 570 populations within a catchment area are assumed to have a higher risk than urban populations 571 (but see Chika-Igwenyi et al. 2021, where >50% of patients in one outbreak were urban 572 residents). For NiV, rural populations and people drinking raw date palm sap could be targeted 573 for vaccination (Rahman et al. 2012; Islam et al. 2016).

574

575 In addition to providing an estimate of vaccine stockpile size, our modeling approach also 576 provides an estimate of where the stockpile will most frequently need to be deployed. An 577 understanding of the geographical distribution of vaccine demand is critical for sustainable 578 manufacturing and timely response to outbreaks (Grais et al. 2008; Azman and Lessler 2015; 579 Wells et al. 2019). Knowledge of vaccine needs by geographic area is essential so that the 580 stockpile(s) can be strategically positioned for rapid deployment following the triggering of an 581 outbreak response. Vaccine demand in a given area will be a function of the probability of an 582 outbreak response being triggered and the size of the target population. Because we used a 583 sliding time window for the outbreak threshold, the probability of a reactive vaccination 584 campaign being triggered will also depend on the seasonality of spillover. Spillover cases that are highly seasonal will be more likely to trigger a response than spillovers that occur 585 586 sporadically throughout the year. Highly seasonal spillover rates also increase the importance of 587 rapid deployment of reactive vaccination campaigns, because the shorter duration of the 588 transmission season increases the likelihood that any delays would cause campaigns to occur 589 only after seasonal spillover transmission has declined. 590

591 The size of the outbreak-response catchment areas (our baseline catchment area at the 2nd 592 administrative level vs. 1st administrative units or individual hospitals within each 1st 593 administrative unit) also had a large impact on the frequency and timing of outbreak response. 594 First-level administrative catchment areas triggered more outbreak responses and also have 595 larger population sizes, and would therefore require a larger vaccine stockpile. However, this 596 result assumes that the outbreak threshold (number of cases needed to trigger a reactive 597 vaccination campaign) is the same regardless of the size of the catchment area. Adjusting the 598 threshold size based on the geographic extent or population size of the catchment areas would 599 alter the stockpile requirements and could be one approach to aligning expected stockpile 600 demands with manufacturing capacity. The expected number of regimens needed for adm1 601 catchment areas might also be an overestimate if only certain regions in an adm1 are at risk. 602 Therefore, another approach that could balance the advantage of expanded adm1 catchment 603 surveillance areas against the larger stockpile requirements would be to monitor spillover cases 604 at the adm1 level, but limit reactive vaccination to the adm2 regions within the adm1 catchment 605 area where spillover cases were observed.

606

607 Vaccination impact

608

609 Our results indicate that reactive vaccination strategies for preventing the transmission of 610 zoonotic pathogens with $R_0 < 1$ tend to have limited impacts. For each of the four pathogens we 611 considered, reactive vaccination of the general population averted fewer than 100 cases per 612 year on average and required more than 10,000 vaccine regimens per case averted. The 613 largest impact (as measured by total cases averted or fraction of cases averted) was achieved 614 for RVFV, which was the only pathogen where >5% of total cases were averted via reactive 615 vaccination under our default assumptions. On a cases-averted per regimen basis, vaccinating 616 HCWs was more effective than vaccinating the general population for each of the pathogens 617 with at least some human-to-human transmission in nosocomial settings (LASV, MERS-CoV, 618 and NiV), suggesting that targeting this group may be a viable strategy for reducing the spread 619 of zoonotic pathogens that are capable of nosocomial transmission.

620

621 Under our baseline reactive vaccination scenario, vaccination averted a higher proportion of 622 RVF cases than cases of the other three diseases, even though we assumed that there was no 623 human-to-human RVFV transmission. The higher impact of reactive vaccination for RVFV was 624 the result of two factors. First, our default threshold to trigger an RVFV vaccination campaign 625 was three cases (compared to 10 cases within a 28-day window for LASV or MERS-CoV), 626 which led to more RVFV campaigns being triggered than for the other diseases. Second, RVFV 627 spillovers are highly clustered in space and time, so additional spillover cases were often 628 concentrated in catchment areas where previous spillovers during the transmission season had 629 already triggered a reactive vaccination campaign. Although the lower threshold led to more 630 vaccine regimens being required for RVFV than for the other pathogens, the per regimen impact 631 of reactive vaccination was still highest for RVFV. These results highlight the importance of 632 understanding the underlying epidemiology of zoonotic pathogens when assessing the 633 feasibility of a reactive vaccination strategy. The spatial and temporal heterogeneity in spillover 634 patterns will be a primary factor determining the potential impact of reactive vaccination for

pathogens where cases primarily occur via zoonotic spillover rather than human-to-human
 transmission. With a sensitive case threshold for triggering a vaccination campaign, and a

- 637 relatively quick response time (28 days), our results indicate that ~25% of RVF cases could be
- 638 averted. However, if the response time is slower (120 days), fewer than 5% of RVF cases would
- be averted via reactive vaccination. This highlights the importance of rapid response and
- 640 vaccine deployment to the success of reactive campaigns when spillover is seasonal.
- 641

642 After RVFV, the impact of vaccination was modestly higher for the pathogen (MERS-CoV) with 643 the highest R₀ (baseline R₀=0.58), indicating that rapid deployment of a reactive vaccination 644 campaign can avert a fraction of cases for pathogens capable of at least some sustained 645 human-to-human transmission. However, even for MERS-CoV, fewer than 10% of annual cases 646 were averted by reactive vaccination, even under our most optimistic scenario with a minimal 647 delay. This was partly because a significant fraction of cases were spillover cases in geographic 648 areas where no vaccination campaign was triggered, and partially because reactive vaccination 649 often did not occur rapidly enough to avert a significant proportion of cases resulting from 650 secondary human-to-human transmission. The one scenario where reactive vaccination had a 651 large impact on MERS-CoV transmission was with a higher R_0 value of 0.99. In this case, 84.0% 652 (95% PrI: 10.7-97.5%) of MERS cases could be averted under our baseline reactive vaccination 653 scenario, compared to only 2.1% (95% PrI: 0-18.2%) of cases averted with the default $R_0=0.58$. 654 This result highlights the increased potential impactof a reactive vaccination strategy as R_0 655 approaches or exceeds one and self-sustaining human-to-human transmission chains that lead 656 to larger outbreaks become more likely.

- 657
- 658 Reactive vs. prophylactic vaccination

659

660 Delays between the triggering of the outbreak threshold and vaccine administration limit the 661 impact of reactive vaccination. In most simulated outbreaks, the outbreak died out before the 662 vaccination was administered due to the low R_0 . In light of this, prophylactic immunization of 663 HCWs or people at high risk could have a larger impact than reactive vaccination. However, a 664 potentially important aspect that was not considered in our study was the impact that reactive 665 vaccination campaigns in one year had for protection in subsequent year(s). Depending on the 666 duration of vaccine-derived immunity, the number of cases averted in subsequent years could 667 be substantial, particularly if the geographic clustering of spillovers is fairly consistent from year 668 to year. For example, in the past few years, some catchment areas in Nigeria have experienced 669 outbreaks of Lassa fever multiple years in a row (Siddle et al. 2018; Roberts 2018). As an 670 extension of our work, the number of averted cases in the years following a reactive vaccination 671 campaign could be estimated based on the spillover rate, the probability of an outbreak, and the 672 durability of vaccine-derived immunity.

673

674 Limitations

675

- 676 We have attempted to estimate vaccine stockpile needs and identify the most important
- 677 determinants of success for reactive vaccination of zoonotic emerging pathogens by modeling
- 678 several vaccination strategies and exploring the sensitivity of our results to different aspects of

pathogen natural history and vaccine deployment. However, there are some limitations to our
 approach that could affect these estimates. We briefly mention the main limitations here and
 include an expanded discussion of these limitations in the SI Text.

682

683 First, there is a relatively poor understanding of the epidemiology of most emerging zoonotic 684 pathogens, and data that could be used to try and elucidate the most important aspects of their 685 epidemiology is limited (Grange et al. 2021). In this study, we collated epidemiological data and 686 parameter estimates from a variety of published sources and also consulted pathogen-specific 687 experts, but, inevitably, our approach was limited by current knowledge. Second, because the 688 modeling framework is intended to be applicable for a range of emerging zoonotic pathogens, it 689 cannot incorporate all of the specific epidemiological details that might affect vaccine demand or 690 impact for a particular pathogen. Our focus was on the key aspects of epidemiology and 691 outbreak response that influence sustainable manufacturing needs, vaccine stockpile 692 requirements, and the impact of outbreak response. Third, we only considered reported cases 693 when estimating pathogen spillover rates, because undiagnosed or unreported infections would 694 not trigger an outbreak response, which could bias the geographic distribution of vaccine 695 demand away from areas with limited disease surveillance systems. This decision was made to 696 ensure that our framework could be implemented with existing data only, and therefore could be 697 applied to other pathogens in a straightforward manner.

698

699 Fourth, because the extent of community transmission for each of the study pathogens is poorly 700 understood, we assumed that human-to-human transmission was limited to nosocomial 701 settings, which could result in an underestimate of vaccine demand. However, our modeling 702 framework could be used to explicitly represent community transmission dynamics, and for 703 pathogens with $R_0 << 1$, as was largely the case in this study, the limited size of the modeled 704 transmission chains would be similar in either a community or hospital setting since we did not 705 restrict the potential number of contacts per index case. Fifth, we also assumed that all 706 nosocomial transmission was from patients to HCWs or between HCWs, and that there was no 707 patient-to-patient or HCW-to-patient transmission. Therefore, our estimates of the impact of 708 vaccinating HCWs represents an upper-bound on the effectiveness of this strategy, as 709 instances of patient-to-patient transmission would not be prevented via this strategy. Sixth, 710 another simplifying assumption of our model is that cases in one catchment area do not lead to 711 transmission or an outbreak outside of that catchment area. However, our model already 712 implicitly incorporates the possibility of spread between catchment areas, and although our 713 model does not predict spillover cases occurring outside of each pathogen's currently 714 documented geographic distribution, the reactive vaccination strategies we examined should 715 also be applicable for responding to imported cases and their associated outbreaks. Finally, we 716 did not consider any targeted vaccination strategies beyond ring vaccination or targeting 717 healthcare workers to limit nosocomial outbreaks. 718

719 Conclusion

720

- To inform the development of sustainable vaccine manufacturing processes for emerging
- pathogens, we developed a modeling framework to estimate the necessary reactive vaccine

723 stockpile size for emerging zoonotic pathogens. Our framework provides a flexible methodology 724 for estimating vaccine stockpile needs for outbreak response, and for exploring the impact of 725 epidemiology and vaccination strategies on outcomes that have important logistical implications 726 for sustainable vaccine manufacturing, such as the geographic distribution of demand or the 727 required stockpile replenishment rate. However, our model showed that the impact of reactive 728 vaccination for the four pathogens that we explored was minimal, preventing fewer than 10% of 729 human cases under most scenarios with their current epidemiology. However, all these 730 pathogens are closely monitored for their outbreak potential, and control measures are needed. 731 Targeting populations at higher risk of infection, such as HCWs, had a higher per-regimen 732 impact than population-wide vaccination in outbreak control situations. Our results highlight the 733 need for a more thorough epidemiological understanding of these, and other, emerging zoonotic 734 pathogens. Improved pathogen surveillance and case detection are also essential for improving 735 the model and our estimates of vaccine demand. Further work exploring additional scenarios, 736 such as the possibility of targeting certain high-risk populations or the potential uses of vaccines 737 for outbreak prevention rather than just outbreak response, is also needed to improve the 738 potential impacts of vaccination. 739 740 **Acknowledgements**

741

742 We thank Jim Robinson of CEPI and several members of the CEPI Scientific Advisory

743 committee for helping formulate the reactive vaccination strategies examined in this manuscript

and for providing feedback on our modeling framework. We thank John Edmunds (LASV),

Robert Sumaye (RVFV), Bart Haagmans (MERS-CoV), Emily Gurley (NiV), and Steve Luby

746 (NiV) for serving as pathogen-specific experts and providing assistance with identifying key

epidemiological features and data gaps for their respective pathogens. We thank Nico Vandaele

for feedback on how epidemiological modeling can help inform the planning and development of

sustainable vaccine manufacturing. We thank Shweta Bansal and Romain Garnier for

discussions regarding the modeling of emerging infectious disease outbreaks and vaccination.

751

753

752 Funding

The following authors were supported by a contract from CEPI to the University of Notre Dame:

AL, QAtB, QMT, JHH, ASS, ME, CH, KK, KS, MW, TAP, SMM.

- 756 Supplementary Information
- 757
- 758 Table S1. Overview of data references.
- 759 Figure S1. Spillover and reactive vaccination patterns for Lassa fever virus (LASV).
- 760 Figure S2. Spillover and reactive vaccination patterns for Middle Eastern respiratory
- 761 virus (MERS-CoV).
- 762 Figure S3. Spillover and reactive vaccination patterns for Nipah virus (NiV).
- 763 Figure S4. Spillover and reactive vaccination patterns for Rift Valley fever virus (RVFV).
- 764 SI Text. Sensitivity analysis.
- 765 Figures S5-S34 in SI Text.
- 766
- 767
- 768

769 **References**

770

- 771
- Ahmad, Khabir. 2000. "More Deaths from Rift Valley Fever in Saudi Arabia and Yemen." *The Lancet* 356 (9239): 1422.
- Ajayi, Nnennaya A. 2013. "Containing a Lassa Fever Epidemic in a Resource-Limited Setting:
 Outbreak Description and Lessons Learned from Abakaliki, Nigeria (January–March
 2012)." International Journal of Infectious Diseases: IJID: Official Publication of the
 International Society for Infectious Diseases 17 (11): e1011–16.
- Al-Hamdan, Nasser A., Anil A. Panackal, Tami H. Al Bassam, Abdullah Alrabea, Mohammed Al Hazmi, Yagoub Al Mazroa, Mohammed Al Jefri, Ali S. Khan, and Thomas G. Ksiazek.
 2015. "The Risk of Nosocomial Transmission of Rift Valley Fever." *PLoS Neglected Tropical Diseases* 9 (12): e0004314.
- Ali, Mohammad, Amanda K. Debes, Francisco J. Luquero, Deok Ryun Kim, Je Yeon Park,
 Laura Digilio, Byomkesh Manna, et al. 2016. "Potential for Controlling Cholera Using a
 Ring Vaccination Strategy: Re-Analysis of Data from a Cluster-Randomized Clinical
 Trial." *PLoS Medicine* 13 (9): e1002120.
- Andersen, Kristian G., Andrew Rambaut, W. Ian Lipkin, Edward C. Holmes, and Robert F.
 Garry. 2020. "The Proximal Origin of SARS-CoV-2." *Nature Medicine* 26 (4): 450–52.
- Anthony, S. J., K. Gilardi, V. D. Menachery, T. Goldstein, B. Ssebide, R. Mbabazi, I. NavarreteMacias, et al. 2017. "Further Evidence for Bats as the Evolutionary Source of Middle
 East Respiratory Syndrome Coronavirus." *MBio* 8 (2).
 https://doi.org/10.1128/mBio.00373-17.
- Antia, Rustom, Roland R. Regoes, Jacob C. Koella, and Carl T. Bergstrom. 2003. "The Role of Evolution in the Emergence of Infectious Diseases." *Nature* 426 (6967): 658–61.
- Anyamba, Assaf, Jean-Paul Chretien, Jennifer Small, Compton J. Tucker, Pierre B. Formenty,
 Jason H. Richardson, Seth C. Britch, David C. Schnabel, Ralph L. Erickson, and
 Kenneth J. Linthicum. 2009. "Prediction of a Rift Valley Fever Outbreak." *Proceedings of*the National Academy of Sciences of the United States of America 106 (3): 955–59.
- Anyamba, Assaf, Kenneth J. Linthicum, Jennifer Small, Seth C. Britch, Edwin Pak, Stephane de
 La Rocque, Pierre Formenty, et al. 2010. "Prediction, Assessment of the Rift Valley
 Fever Activity in East and Southern Africa 2006–2008 and Possible Vector Control
 Strategies." *The American Journal of Tropical Medicine and Hygiene* 83 (2_Suppl): 43–
 51.
- Archer, B. N., J. Thomas, J. Weyer, A. Cengimbo, D. E. Landoh, C. Jacobs, S. Ntuli, et al. 2013.
 "Epidemiologic Investigations into Outbreaks of Rift Valley Fever in Humans, South
 Africa, 2008-2011." *Emerging Infectious Diseases* 19 (12).
- 806 https://doi.org/10.3201/eid1912.121527.
- Arunkumar, Govindakarnavar, Radhakrishnan Chandni, Devendra T. Mourya, Sujeet K. Singh,
 Rajeev Sadanandan, Preeti Sudan, Balram Bhargava, and Nipah Investigators People
 and Health Study Group. 2019. "Outbreak Investigation of Nipah Virus Disease in
 Kerala, India, 2018." *The Journal of Infectious Diseases* 219 (12): 1867–78.
- Assiri, Abdullah, Jaffar A. Al-Tawfiq, Abdullah A. Al-Rabeeah, Fahad A. Al-Rabiah, Sami AlHajjar, Ali Al-Barrak, Hesham Flemban, et al. 2013. "Epidemiological, Demographic, and
 Clinical Characteristics of 47 Cases of Middle East Respiratory Syndrome Coronavirus
 Disease from Saudi Arabia: A Descriptive Study." *The Lancet Infectious Diseases* 13 (9):
 752–61.
- Assiri, Abdullah, Allison McGeer, Trish M. Perl, Connie S. Price, Abdullah A. Al Rabeeah, Derek
 A. T. Cummings, Zaki N. Alabdullatif, et al. 2013. "Hospital Outbreak of Middle East
 Respiratory Syndrome Coronavirus." *The New England Journal of Medicine* 369 (5):

819	407–16.
820	Bernasconi, Valentina, Paul A. Kristiansen, Mike Whelan, Raúl Gómez Román, Alison Bettis,
821	Solomon Abebe Yimer, Céline Gurry, et al. 2020. "Developing Vaccines against
822	Epidemic-Prone Emerging Infectious Diseases." Bundesgesundheitsblatt.
823	Gesundheitsforschung. Gesundheitsschutz 63 (1): 65–73.
824	Bird, Brian H., Thomas G. Ksiazek, Stuart T. Nichol, and N. James Maclachlan, 2009, "Rift
825	Valley Fever Virus " Journal of the American Veterinary Medical Association 234 (7)
826	883-93
827	Bob Ndeve Sakha Hampâté Bâ Gamou Fall Elkhalil Ishaqh Mamadou Y Diallo
828	Abdourahmane Sow Pape Mbacké Sembene, et al. 2017 "Detection of the
829	Northeastern African Rift Valley Fever Virus Lineage During the 2015 Outbreak in
830	Mauritania " Open Forum Infectious Diseases 4 (2) https://doi.org/10.1093/ofid/ofx087
831	Bowen G S O Tomori H Wulff J Casals A Noonan and W G Downs 1975 "Lassa Fever
832	in Onitsha Fast Central State Nigeria in 1974 " <i>Bulletin of the World Health</i>
833	Organization 52 (4–6): 599–604
834	Brehan Romulus Julien Riou and Arnaud Fontanet 2013 "Interhuman Transmissibility of
835	Middle East Respiratory Syndrome Coronavirus: Estimation of Pandemic Risk " The
836	Lancet 382 (9803): 601_00
837	Bron Gebbiena M. Kathryn Strimbu, Helene Cecilia, Anita Lerch, Sean M. Moore, Quan Tran
838	T Alex Perkins and A Quirine 2021 "Over 100 Years of Rift Valley Fever: A Patchwork
839	of Data on Pathogen Spread and Spillover " Pathogens 10 (6): 708
840	Brooks Mollie F. Kasper Kristensen, Koen J. Van Benthem Arni Magnusson, Casper W. Berg
841	Anders Nielsen, Hans J. Skaug Martin Machler, and Benjamin M. Bolker. 2017
842	"GlmmTMB Balances Speed and Elevibility among Packages for Zero-Inflated
843	Generalized Linear Mixed Modeling " The R Journal 9 (2): 378–400
844	Buhar Kate M, Kyle Reinholt, Stenhen M, Kissler, Marc Linsitch, Sarah Cobey, Yonatan H
845	Grad and Daniel B Larremore 2021 "Model-Informed COVID-19 Vaccine Prioritization
846	Strategies by Age and Serostatus " Science, https://doi.org/10.1126/science.abe6959
847	Carey D E G E Kemp H A White I Pinneo R E Addy A I Fom G Strob I Casals
848	and B. F. Henderson, 1972 "Lassa Fever, Epidemiological Aspects of the 1970
849	Epidemic Jos Nigeria "Transactions of the Royal Society of Tropical Medicine and
850	Hydiene 66 (3): 402–8
851	Cauchemez Simon Christophe Fraser Maria D Van Kerkhove Christl A Donnelly Steven
852	Riley Andrew Rambaut Vincent Enouf Sylvie van der Werf and Neil M Ferguson
853	2014 "Middle East Respiratory Syndrome Coronavirus: Quantification of the Extent of
854	the Enidemic Surveillance Biases and Transmissibility "The Lancet Infectious Diseases
855	14 (1): 50–56
856	Cauchemez Simon Pierre Nouvellet Anne Cori Thibaut Jombart Tini Garske Hannah
857	Clapham Sean Moore et al. 2016 "Unraveling the Drivers of MERS-CoV
858	Transmission " Proceedings of the National Academy of Sciences of the United States of
859	America 113 (32): 9081–86
860	Centers for Disease Control and Prevention (CDC) 1998 "Rift Valley Fever Fast Africa
861	1997-1998 " MMWR Morb Mortal Wkly Rep 47 (13): 261–64
862	2007 "Rift Valley Fever Outbreak Kenva, November 2006 January 2007 " MMWR
863	Morb Mortal Wkly Rep 56 (4): 73–76
864	2020 "Outbreak Summaries: Rift Valley Fever " June 1, 2020
865	https://www.cdc.gov/vhf/rvf/outbreaks/summaries.html
866	CEPI. 2018. "Priority Diseases – CEPI." December 12, 2018
867	https://cepi.net/research_dev/priority-diseases/
868	Chan, K. P., P. E. Rollin, T. G. Ksjazek, Y. S. Leo, K. T. Goh, N. I. Paton, E. H. Sng and A. F.
869	Ling. 2002a. "A Survey of Nipah Virus Infection among Various Risk Groups in

870 Singapore." Epidemiology and Infection 128 (1): 93-98. 871 . 2002b. "A Survey of Nipah Virus Infection among Various Risk Groups in Singapore." Epidemiology & Infection 128 (1): 93–98. 872 873 Chowell, Gerardo, Seth Blumberg, Lone Simonsen, Mark A. Miller, and Cécile Viboud. 2014. 874 "Synthesizing Data and Models for the Spread of MERS-CoV, 2013: Key Role of Index 875 Cases and Hospital Transmission." Epidemics 9 (December): 40-51. 876 CSR. n.d. "World Health Organization - Eastern Mediterranean Region." Accessed March 19, 877 2019. http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-878 update-february-2019.html. 879 Daubney, R., J. R. Hudson, and P. C. Garnham. 1931. "Enzootic Hepatitis or Rift Valley Fever. 880 An Undescribed Virus Disease of Sheep Cattle and Man from East Africa." The Journal 881 of Pathology and Bacteriology 34 (4): 545–79. 882 Dudas, Gytis, Luiz Max Carvalho, Andrew Rambaut, and Trevor Bedford. 2018. "MERS-CoV 883 Spillover at the Camel-Human Interface." ELife 7 (January). 884 https://doi.org/10.7554/eLife.31257. 885 E Keane, H. M. Gilles. 1977. "Lassa Fever in Panguma Hospital, Sierra Leone, 1973-6." British 886 Medical Journal 1 (6073): 1399. 887 Excler, Jean-Louis, Melanie Saville, Seth Berkley, and Jerome H. Kim. 2021. "Vaccine 888 Development for Emerging Infectious Diseases." Nature Medicine 27 (4): 591–600. 889 FAO. 2017. "Rift Valley Fever in Niger: Risk Assessment." 890 http://www.fao.org/3/i7055e/i7055e.pdf. 891 Farrington, C. P., M. N. Kanaan, and N. J. Gay. 2003. "Branching Process Models for 892 Surveillance of Infectious Diseases Controlled by Mass Vaccination." Biostatistics 4 (2): 893 279-95. 894 Faye, Ousmane, Mawlouth Diallo, Djibril Diop, O. Elmamy Bezeid, Hampathé Bâ, Mbayame 895 Niang, Ibrahima Dia, et al. 2007. "Rift Valley Fever Outbreak with East-Central African 896 Virus Lineage in Mauritania, 2003." Emerging Infectious Diseases 13 (7): 1016. 897 Findlay, G. M. 1932. "Rift Valley Fever or Enzootic Hepatitis." *Transactions of the Royal Society* 898 of Tropical Medicine and Hygiene 25 (4): 229-IN11. 899 Fisher-Hoch, S. P., O. Tomori, A. Nasidi, G. I. Perez-Oronoz, Y. Fakile, L. Hutwagner, and J. B. 900 McCormick. 1995. "Review of Cases of Nosocomial Lassa Fever in Nigeria: The High 901 Price of Poor Medical Practice." BMJ 311 (7009): 857-59. 902 Frame, J. D., J. M. Baldwin Jr, D. J. Gocke, and J. M. Troup. 1970. "Lassa Fever, a New Virus 903 Disease of Man from West Africa. I. Clinical Description and Pathological Findings." The 904 American Journal of Tropical Medicine and Hygiene 19 (4): 670–76. 905 Francis, T., and T. P. Magill. 1935. "RIFT VALLEY FEVER : A REPORT OF THREE CASES OF 906 LABORATORY INFECTION AND THE EXPERIMENTAL TRANSMISSION OF THE 907 DISEASE TO FERRETS." The Journal of Experimental Medicine 62 (3): 433–48. Fraser, D. W., C. C. Campbell, T. P. Monath, P. A. Goff, and M. B. Gregg. 1974. "Lassa Fever 908 909 in the Eastern Province of Sierra Leone, 1970-1972. I. Epidemiologic Studies." The 910 American Journal of Tropical Medicine and Hygiene 23 (6): 1131–39. 911 Gerken, Keli N., A. Desiree LaBeaud, Henshaw Mandi, Maina L'Azou Jackson, J. Gabrielle 912 Breugelmans, and Charles H. King. 2021. "Paving the Way for Human Vaccination 913 against Rift Valley Fever Virus: 1 A Systematic Literature Review of RVFV Epidemiology 914 from 1999 to 2021." MedRxiv. https://doi.org/10.1101/2021.09.29.21264307. 915 Gibb, Rory, Lina M. Moses, David W. Redding, and Kate E. Jones. 2017. "Understanding the 916 Cryptic Nature of Lassa Fever in West Africa." Pathogens and Global Health 111 (6): 917 276-88. 918 Girish Kumar, C. P., Attayur P. Sugunan, Pragya Yadav, Karishma Krishna Kurup, Renjith 919 Aarathee, Ponnaiah Manickam, Tarun Bhatnagar, et al. 2019. "Infections among 920 Contacts of Patients with Nipah Virus, India." Emerging Infectious Diseases Journal 25

921	(5). https://doi.org/10.3201/eid2505.181352.
922	Gouglas, Dimitrios, Mario Christodoulou, Stanley A. Plotkin, and Richard Hatchett. 2019. "CEPI:
923	Driving Progress Toward Epidemic Preparedness and Response." Epidemiologic
924	Reviews 41 (1): 28–33.
925	Grange, Zoë L., Tracey Goldstein, Christine K. Johnson, Simon Anthony, Kirsten Gilardi, Peter
926	Daszak, Kevin J. Olival, et al. 2021. "Ranking the Risk of Animal-to-Human Spillover for
927	Newly Discovered Viruses." Proceedings of the National Academy of Sciences of the
928	United States of America 118 (15). https://doi.org/10.1073/pnas.2002324118.
929	Group, The Who Mers-Cov Research, and The WHO MERS-CoV Research Group. 2013.
930	"State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus
931	(MERS-CoV) in Humans." <i>PLoS Currents</i> .
932	https://doi.org/10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8.
933	Gurley, Emily S., Joel M. Montgomery, M. Jahangir Hossain, Michael Bell, Abul Kalam Azad,
934	Mohammed Rafiqul Islam, Mohammed Abdur Rahim Molla, et al. 2007. "Person-to-
935	Person Transmission of Nipah Virus in a Bangladeshi Community." Emerging Infectious
936	Diseases 13 (7): 1031–37.
937	Gurley, Emily S., Joel M. Montgomery, M. Jahangir Hossain, M. Rafiqul Islam, M. Abdur Rahim
938	Molla, S. M. Shamsuzzaman, Kazi Akram, et al. 2007. "Risk of Nosocomial
939	Transmission of Nipah Virus in a Bangladesh Hospital." Infection Control and Hospital
940	Epidemiology: The Official Journal of the Society of Hospital Epidemiologists of America
941	28 (6): 740–42.
942	Hamblion, E. L., P. Raftery, A. Wendland, E. Dweh, G. S. Williams, R. N. C. George, L. Soro, et
943	al. 2018. "The Challenges of Detecting and Responding to a Lassa Fever Outbreak in an
944	Ebola-Affected Setting." International Journal of Infectious Diseases: IJID: Official
945	Publication of the International Society for Infectious Diseases 66 (January): 65–73.
946	Henao-Restrepo, Ana Maria, Anton Camacho, Ira M. Longini, Conall H. Watson, W. John
947	Edmunds, Matthias Egger, Miles W. Carroll, et al. 2017. "Efficacy and Effectiveness of
948	an RVSV-Vectored Vaccine in Preventing Ebola Virus Disease: Final Results from the
949	Guinea Ring Vaccination, Open-Label, Cluster-Randomised Trial (Ebola Ça Suffit!)." The
950	<i>Lancet</i> . https://doi.org/10.1016/s0140-6736(16)32621-6.
951	Hoogstraal, H., J. M. Meegan, G. M. Khalil, and F. K. Adham. 1979. "The Rift Valley Fever
952	Epizootic in Egypt 1977-78. 2. Ecological and Entomological Studies." Transactions of
953	the Royal Society of Tropical Medicine and Hygiene 73 (6): 624–29.
954	Hsu, Vincent P., Mohammed Jahangir Hossain, Umesh D. Parashar, Mohammed Monsur Ali,
955	Thomas G. Ksiazek, Ivan Kuzmin, Michael Niezgoda, Charles Rupprecht, Joseph
956	Bresee, and Robert F. Breiman. 2004. "Nipah Virus Encephalitis Reemergence,
957	Bangladesh." <i>Emerging Infectious Diseases</i> 10 (12): 2082–87.
958	Hui, David S., Esam I. Azhar, Yae-Jean Kim, Ziad A. Memish, Myoung-Don Oh, and Alimuddin
959	Zumla. 2018. "Middle East Respiratory Syndrome Coronavirus: Risk Factors and
960	Determinants of Primary, Household, and Nosocomial Transmission." The Lancet
961	Infectious Diseases 18 (8): e217–27.
962	Huneycutt, Brenda, Nicole Lurie, Sara Rotenberg, Richard Wilder, and Richard Hatchett. 2020.
963	"Finding Equipoise: CEPI Revises Its Equitable Access Policy." Vaccine 38 (9): 2144–
964	48.
965	Islam, M. Saiful, Hossain M. S. Sazzad, Syed Moinuddin Satter, Sharmin Sultana, M. Jahangir
966	Hossain, Murshid Hasan, Mahmudur Rahman, et al. 2016. "Nipah Virus Transmission
967	from Bats to Humans Associated with Drinking Traditional Liquor Made from Date Palm
968	Sap, Bangladesh, 2011-2014." <i>Emerging Infectious Diseases</i> 22 (4): 664–70.
969	Jouan, A., B. Le Guenno, J. P. Digoutte, B. Philippe, O. Riou, and F. Adam. 1988. "An RVF
970	Epidemic in Southern Mauritania." Annales de l'Institut Pasteur. Virology 139 (3).
971	https://doi.org/10.1016/s0769-2617(88)80046-7.

- 872 Kernéis, Solen, Lamine Koivogui, N'faly Magassouba, Kekoura Koulemou, Rosamund Lewis,
 873 Aristide Aplogan, Rebecca F. Grais, Philippe J. Guerin, and Elisabeth Fichet-Calvet.
 874 2009. "Prevalence and Risk Factors of Lassa Seropositivity in Inhabitants of the Forest
 875 Region of Guinea: A Cross-Sectional Study." *PLoS Neglected Tropical Diseases*.
 876 https://doi.org/10.1371/journal.pntd.0000548.
- Khan, S. H., A. Goba, M. Chu, C. Roth, T. Healing, A. Marx, J. Fair, et al. 2008. "New
 Opportunities for Field Research on the Pathogenesis and Treatment of Lassa Fever." *Antiviral Research* 78 (1): 103–15.
- Ki, Moran. 2015. "2015 MERS Outbreak in Korea: Hospital-to-Hospital Transmission."
 Epidemiology and Health 37 (July): e2015033.
- Kitchen, S. F. 1934. "Laboratory Infections with the Virus of Rift Valley Fever 1." *The American Journal of Tropical Medicine and Hygiene* s1-14 (6): 547–64.
- Kucharski, A. J., and C. L. Althaus. 2015. "The Role of Superspreading in Middle East
 Respiratory Syndrome Coronavirus (MERS-CoV) Transmission." *Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease*Bulletin 20 (25): 14–18.
- Kumar, C. P. Girish, Attayur P. Sugunan, Pragya Yadav, Karishma Krishna Kurup, Renjith
 Aarathee, Ponnaiah Manickam, Tarun Bhatnagar, et al. 2019. "Infections among
 Contacts of Patients with Nipah Virus, India." *Emerging Infectious Diseases* 25 (5):
 1007–10.
- Laughlin, Larry W., James M. Meegan, Larry J. Strausbaugh, David M. Morens, and Raymond
 H. Watten. 1979. "Epidemic Rift Valley Fever in Egypt: Observations of the Spectrum of
 Human Illness." *Transactions of the Royal Society of Tropical Medicine and Hygiene* 73
 (6): 630–33.
- Lee, Elizabeth C., Nikolas I. Wada, M. Kate Grabowski, Emily S. Gurley, and Justin Lessler.
 2020. "The Engines of SARS-CoV-2 Spread." *Science* 370 (6515): 406–7.
- Linthicum, Kenneth J., Seth C. Britch, and Assaf Anyamba. 2016. "Rift Valley Fever: An
 Emerging Mosquito-Borne Disease." *Annual Review of Entomology* 61: 395–415.
- Lo Iacono, G., A. A. Cunningham, E. Fichet-Calvet, R. F. Garry, D. S. Grant, S. H. Khan, M.
 Leach, et al. 2015. "Using Modelling to Disentangle the Relative Contributions of
 Zoonotic and Anthroponotic Transmission: The Case of Lassa Fever." *PLoS Neglected Tropical Diseases* 9 (1). https://doi.org/10.1371/journal.pntd.0003398.
- Luby, Stephen P., M. Jahangir Hossain, Emily S. Gurley, Be Nazir Ahmed, Shakila Banu, Salah
 Uddin Khan, Nusrat Homaira, et al. 2009. "Recurrent Zoonotic Transmission of Nipah
 Virus into Humans, Bangladesh, 2001-2007." *Emerging Infectious Diseases* 15 (8):
 1229–35.
- Maina, Joseph, Paul O. Ouma, Peter M. Macharia, Victor A. Alegana, Benard Mitto, Ibrahima
 Socé Fall, Abdisalan M. Noor, Robert W. Snow, and Emelda A. Okiro. 2019. "A Spatial
 Database of Health Facilities Managed by the Public Health Sector in Sub Saharan
 Africa." *Scientific Data* 6 (1): 134.
- McCormick, J. B., P. A. Webb, J. W. Krebs, K. M. Johnson, and E. S. Smith. 1987. "A
 Prospective Study of the Epidemiology and Ecology of Lassa Fever." *The Journal of Infectious Diseases* 155 (3): 437–44.
- Medlock, Jan, and Alison P. Galvani. 2009. "Optimizing Influenza Vaccine Distribution." *Science* 325 (5948): 1705–8.
- 1017 "MERS-CoV Cases." n.d. Accessed December 4, 2020. http://rambaut.github.io/MERS 1018 Tools/cases2.html.
- Métras, Raphaëlle, Lisa Cavalerie, Laure Dommergues, Philippe Mérot, W. John Edmunds,
 Matt J. Keeling, Catherine Cêtre-Sossah, and Eric Cardinale. 2016. "The Epidemiology
 of Rift Valley Fever in Mayotte: Insights and Perspectives from 11 Years of Data." *PLoS Neglected Tropical Diseases* 10 (6). https://doi.org/10.1371/journal.pntd.0004783.

1023 Meulen, J. ter, O. Lenz, L. Koivogui, N. Magassouba, S. K. Kaushik, R. Lewis, and W. Aldis. 1024 2001. "Short Communication: Lassa Fever in Sierra Leone: UN Peacekeepers Are at 1025 Risk." Tropical Medicine & International Health: TM & IH 6 (1): 83–84. 1026 "Ministry of Health - Kingdom of Saudi Arabia." 2020. 2020. 1027 https://www.moh.gov.sa/en/CCC/events/national/Pages/2020.aspx. 1028 Monath, T. P. 1974. "Lassa Fever and Marburg Virus Disease." WHO Chronicle 28 (5). 1029 https://pubmed.ncbi.nlm.nih.gov/4208764/. 1030 Monath, T. P., P. E. Mertens, R. Patton, C. R. Moser, J. J. Baum, L. Pinneo, G. W. Gary, and R. E. Kissling. 1973. "A Hospital Epidemic of Lassa Fever in Zorzor, Liberia, March-April 1031 1032 1972." The American Journal of Tropical Medicine and Hygiene 22 (6): 773–79. 1033 Morse, Stephen S., Jonna A. K. Mazet, Mark Woolhouse, Colin R. Parrish, Dennis Carroll, 1034 William B. Karesh, Carlos Zambrana-Torrelio, W. Ian Lipkin, and Peter Daszak. 2012. 1035 "Prediction and Prevention of the next Pandemic Zoonosis." The Lancet 380 (9857): 1036 1956-65. 1037 Msimang, Veerle, Peter N, Thompson, Petrus Jansen van Vuren, Stefano Tempia, Claudia 1038 Cordel, Joe Kgaladi, Jimmy Khosa, et al. 2019. "Rift Valley Fever Virus Exposure 1039 amongst Farmers, Farm Workers, and Veterinary Professionals in Central South Africa." 1040 Viruses 11 (2). https://doi.org/10.3390/v11020140. Müller, Marcel A., Benjamin Meyer, Victor M. Corman, Malak Al-Masri, Abdulhafeez Turkestani, 1041 1042 Daniel Ritz, Andrea Sieberg, et al. 2015. "Presence of Middle East Respiratory 1043 Syndrome Coronavirus Antibodies in Saudi Arabia: A Nationwide, Cross-Sectional, 1044 Serological Study." The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-1045 3099(15)70090-3. 1046 Mundel, B., and J. Gear. 1951. "Rift Valley Fever; I. The Occurrence of Human Cases in 1047 Johannesburg." South African Medical Journal = Suid-Afrikaanse Tydskrif Vir 1048 Geneeskunde 25 (44): 797-800. 1049 Munyua, Peninah M., Isaac Ngere, Elizabeth Hunsperger, Adano Kochi, Patrick Amoth, Lydia 1050 Mwasi, Suxiang Tong, et al. 2021. "Low-Level Middle East Respiratory Syndrome 1051 Coronavirus among Camel Handlers, Kenya, 2019." Emerging Infectious Diseases 27 1052 (4): 1201–5. 1053 Mylne, Adrian Q. N., David M. Pigott, Joshua Longbottom, Freya Shearer, Kirsten A. Duda, 1054 Jane P. Messina, Daniel J. Weiss, Catherine L. Moyes, Nick Golding, and Simon I. Hay. 1055 2015. "Mapping the Zoonotic Niche of Lassa Fever in Africa." Transactions of the Royal 1056 Society of Tropical Medicine and Hygiene 109 (8): 483–92. 1057 Nderitu, Leonard, John S. Lee, Jared Omolo, Sylvia Omulo, Monica L. O'Guinn, Allen 1058 Hightower, Fausta Mosha, et al. 2010. "Sequential Rift Valley Fever Outbreaks in 1059 Eastern Africa Caused by Multiple Lineages of the Virus." The Journal of Infectious 1060 Diseases 203 (5): 655-65. 1061 "Nigeria Centre for Disease Control." n.d. Accessed December 31, 2020. 1062 https://ncdc.gov.ng/diseases/sitreps/?cat=5&name=An%20update%20of%20Lassa%20f 1063 ever%20outbreak%20in%20Nigeria. 1064 Nikolay, Birgit. 2019. "Transmission of Nipah Virus - 14 Years of Investigations in Bangladesh." 1065 The New England Journal of Medicine 380 (19): 1804–14. 1066 Nikolay, Birgit, Henrik Salje, M. Jahangir Hossain, A. K. M. Dawlat Khan, Hossain M. S. Sazzad, 1067 Mahmudur Rahman, Peter Daszak, Ute Ströher, Juliet R. C. Pulliam, A. Marm Kilpatrick, 1068 Stuart T. Nichol, et al. 2019. "Transmission of Nipah Virus - 14 Years of Investigations in 1069 Bangladesh." The New England Journal of Medicine 380 (19): 1804–14. 1070 Nikolay, Birgit, Henrik Salje, M. Jahangir Hossain, Akm Dawlat Khan, Hossain M. S. Sazzad, 1071 Mahmudur Rahman, Peter Daszak, Ute Ströher, Juliet R. C. Pulliam, A. Marm Kilpatrick, 1072 and Others. 2019. "Transmission of Nipah Virus—14 Years of Investigations in 1073 Bangladesh." The New England Journal of Medicine 380 (19): 1804-14.

1074 Nyakarahuka, Luke, Annabelle de St Maurice, Lawrence Purpura, Elizabeth Ervin, Stephen 1075 Balinandi, Alex Tumusiime, Jackson Kyondo, et al. 2018. "Prevalence and Risk Factors 1076 of Rift Valley Fever in Humans and Animals from Kabale District in Southwestern 1077 Uganda, 2016." PLoS Neglected Tropical Diseases 12 (5): e0006412. 1078 O'Hearn, Aileen E., Matthew A. Voorhees, David P. Fetterer, Nadia Wauguier, Moinya R. 1079 Coomber, James Bangura, Joseph N. Fair, Jean-Paul Gonzalez, and Randal J. 1080 Schoepp. 2016. "Serosurveillance of Viral Pathogens Circulating in West Africa." Virology Journal 13 (1): 163. 1081 1082 Overbosch, Femke, Mark de Boer, Karin Ellen Veldkamp, Pauline Ellerbroek, Chantal P. 1083 Bleeker-Rovers, Bram Goorhuis, Michele van Vugt, et al. 2020. "Public Health Response 1084 to Two Imported, Epidemiologically Related Cases of Lassa Fever in the Netherlands 1085 (Ex Sierra Leone), November 2019." Euro Surveillance: Bulletin Europeen Sur Les 1086 Maladies Transmissibles = European Communicable Disease Bulletin 25 (15). 1087 https://doi.org/10.2807/1560-7917.ES.2020.25.15.2000265. 1088 Parashar, U. D., L. M. Sunn, F. Ong, A. W. Mounts, M. T. Arif, T. G. Ksiazek, M. A. Kamaluddin, 1089 et al. 2000. "Case-Control Study of Risk Factors for Human Infection with a New 1090 Zoonotic Paramyxovirus, Nipah Virus, during a 1998-1999 Outbreak of Severe 1091 Encephalitis in Malaysia." The Journal of Infectious Diseases 181 (5): 1755–59. 1092 Park, Sun Hee, Yeon-Sook Kim, Younghee Jung, Soo Young Choi, Nam-Hyuk Cho, Hye Won 1093 Jeong, Jung Yeon Heo, et al. 2016. "Outbreaks of Middle East Respiratory Syndrome in 1094 Two Hospitals Initiated by a Single Patient in Daejeon, South Korea." Infection & 1095 Chemotherapy 48 (2): 99-107. 1096 Pepin, Michel, Michele Bouloy, Brian H. Bird, Alan Kemp, and Janusz Paweska. 2010. "Rift 1097 Valley Fever Virus(Bunyaviridae: Phlebovirus): An Update on Pathogenesis, Molecular 1098 Epidemiology, Vectors, Diagnostics and Prevention." Veterinary Research 41 (6): 61. 1099 Poletto, C., C. Pelat, D. Levy-Bruhl, Y. Yazdanpanah, P. Y. Boelle, and V. Colizza. 2014. 1100 "Assessment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) 1101 Epidemic in the Middle East and Risk of International Spread Using a Novel Maximum Likelihood Analysis Approach." Euro Surveillance: Bulletin Europeen Sur Les Maladies 1102 1103 Transmissibles = European Communicable Disease Bulletin 19 (23). 1104 https://doi.org/10.2807/1560-7917.es2014.19.23.20824. 1105 ProMED-mail. 2020. "ProMED-Mail." 2020. https://promedmail.org/. Pulliam, Juliet R. C., Jonathan H. Epstein, Jonathan Dushoff, Sohayati A. Rahman, Michel 1106 1107 Bunning, Aziz A. Jamaluddin, Alex D. Hyatt, et al. 2012. "Agricultural Intensification, 1108 Priming for Persistence and the Emergence of Nipah Virus: A Lethal Bat-Borne 1109 Zoonosis." Journal of the Royal Society, Interface / the Royal Society 9 (66): 89–101. 1110 Rahman, Muhammad Aziz, Mohammad Jahangir Hossain, Sharmin Sultana, Nusrat Homaira, 1111 Salah Uddin Khan, Mahmudur Rahman, Emily S. Gurley, et al. 2012. "Date Palm Sap 1112 Linked to Nipah Virus Outbreak in Bangladesh, 2008." Vector Borne and Zoonotic 1113 Diseases 12 (1): 65-72. 1114 Reeves, Tarian, Abdallah M. Samy, and A. Townsend Peterson. 2015. "MERS-CoV Geography 1115 and Ecology in the Middle East: Analyses of Reported Camel Exposures and a 1116 Preliminary Risk Map." BMC Research Notes 8 (1): 1–7. 1117 "Rift Valley Fever in Egypt and Other African Countries: Historical Review, Recent Outbreaks 1118 and Possibility of Disease Occurrence in Egypt." 2018. Acta Tropica 181 (May): 40-49. 1119 Roberts, Leslie. 2018. "Nigeria Hit by Unprecedented Lassa Fever Outbreak." Science 359 1120 (6381): 1201-2. 1121 Røttingen, John-Arne, Dimitrios Gouglas, Mark Feinberg, Stanley Plotkin, Krishnaswamy V. 1122 Raghavan, Andrew Witty, Ruxandra Draghia-Akli, Paul Stoffels, and Peter Piot. 2017. 1123 "New Vaccines against Epidemic Infectious Diseases." The New England Journal of 1124 Medicine 376 (7): 610-13.

1125	Saameli, René, Dikolela Kalubi, Mark Herringer, Tim Sutton, and Eric de Roodenbeke. 2018.
1120	Realinsiles.io: The Global Realinsiles Mapping Project. Technologies for
1127	Development. https://doi.org/10.1007/978-3-319-91068-0_5.
1128	Sabin, A. B., and R. W. Blumberg. 1947. "Human Infection with Rift Valley Fever Virus and
1129	Immunity Twelve Years after Single Attack." Proceedings of the Society for Experimental
1130	Biology and Medicine. Society for Experimental Biology and Medicine 64 (4): 385–89.
1131	Sha, Jianping, Yuan Li, Xiaowen Chen, Yan Hu, Yajin Ren, Xingyi Geng, Zhiruo Zhang, and
1132	Shelan Liu. 2017. "Fatality Risks for Nosocomial Outbreaks of Middle East Respiratory
1133	Syndrome Coronavirus in the Middle East and South Korea." Archives of Virology 162
1134	(1): 33–44.
1135	Sheahan, Timothy, Barry Rockx, Eric Donaldson, Amy Sims, Raymond Pickles, Davide Corti,
1136	and Ralph Baric. 2008. "Mechanisms of Zoonotic Severe Acute Respiratory Syndrome
1137	Coronavirus Host Range Expansion in Human Airway Epithelium," Journal of Virology 82
1138	(5): 2274–85
1130	Siddle Katherine I. Philomena Fromon Kayla G. Barnes, Samar Mehta, Judith II. Oquzie
1140	Ikponmwosa Odia, Stenhen F. Schaffner, et al. 2018. "Genomic Analysis of Lassa Virus
11/1	during an Increase in Cases in Nigeria in 2018." The New England Journal of Medicine
1141	270 (19)· 17/5 52
1142	579 (10). 1745–55. Sissaka Daguda Clauda Ciru Bhilippa Cabria Arnaud Tarantala, Eranasia Battinalli, Lauja
1143	Sissoko, Daouda, Claude Giry, Frilippe Gabrie, Arriaud Tataritola, François Feithein, Louis
1144	Movette, 2007, 2000, "Emerging Infontione Diseases 45 (4): 500
1140	Mayolle, 2007–2008. Emerging infectious Diseases 15 (4): 568.
1140	Smithburn, K. C., and A. F. Manaffy. 1949. "Rift Valley Fever; Accidental Infections among
1147	Laboratory vvorkers." Journal of Immunology 62 (2): 213–27.
1148	Sow, Abdourahmane, Ousmane Faye, Yamar Ba, Hampathe Ba, Diawo Diallo, Oumar Faye,
1149	Cheikh Loucoubar, et al. 2014. "Rift Valley Fever Outbreak, Southern Mauritania, 2012."
1150	Emerging Infectious Diseases 20 (2): 296.
1151	Sow, Abdourahmane, Ousmane Faye, Yamar Ba, Diawo Diallo, Gamou Fall, Oumar Faye,
1152	Ndeye Sakha Bob, et al. 2016. "Widespread Rift Valley Fever Emergence in Senegal in
1153	2013–2014." Open Forum Infectious Diseases 3 (3). https://doi.org/10.1093/ofid/ofw149.
1154	Tan, Kay-Sin, Chong Tin Tan, and Khean Jin Goh. 1999. "Epidemiological Aspects of Nipah
1155	Virus Infection." <i>Neurol J Southeast Asia</i> 4 (1): 77–81.
1156	Tatem, Andrew J. 2017. "WorldPop, Open Data for Spatial Demography." Scientific Data 4
1157	(January): 170004.
1158	Tindale, Lauren C., Jessica E. Stockdale, Michelle Coombe, Emma S. Garlock, Wing Yin Venus
1159	Lau, Manu Saraswat, Louxin Zhang, Dongxuan Chen, Jacco Wallinga, and Caroline
1160	Colijn. 2020. "Evidence for Transmission of COVID-19 Prior to Symptom Onset." ELife 9
1161	(June). https://doi.org/10.7554/eLife.57149.
1162	Virlogeux, Victor, Minah Park, Joseph T. Wu, and Benjamin J. Cowling. 2016. "Association
1163	between Severity of MERS-CoV Infection and Incubation Period." Emerging Infectious
1164	Diseases 22 (3): 526–28
1165	WHO 2016 "Prioritizing Diseases for Research and Development in Emergency Contexts"
1166	2016 https://www.who.int/activities/prioritizing-diseases-for-research-and-development-
1167	in-emergency-contexts
1168	2017a "WHO Target Product Profile for Lassa Virus Vaccine "
1160	https://www.wbo.int/blueprint/priority_diseases/key_
1170	action/Lassa//irus//accineTPP_PDF2ua=1
1170	2017b "WHO Target Product Profile for Ninab Virus Vaccine "
1172	https://www.who.int/bluenrint/priority_diseases/key_action/Ningh_virus_vaccingTDD.pdf
1172	2017c "WHO Target Product Profiles for MERS CoV/ Vaccines "
1173	https://www.who.ipt/bluoprint/what/rosearch
11/4	https://www.who.in/bluephil/what/tesearch- dovelopment/MEDS_CoV/_TDD_15052017_pdf2uc=1
11/J	$aevelopment/vieros_cov_ree_rouszur/.par/ua=r.$

1176 -. 2018. "Weekly Bulletin on Outbreaks and Other Emergencies." 2018. 1177 https://apps.who.int/iris/bitstream/handle/10665/273028/OEW27-300606072018.pdf. 1178 . 2019. "Target Product Profiles for Rift Valley Fever Virus Vaccines." 1179 https://www.who.int/docs/default-source/blue-print/call-for-comments/tpp-rift-valley-fever-1180 vaccines-draft3-0pc.pdf?sfvrsn=f2f3b314 2. 1181 -. 2020. "WHO Coronavirus (COVID-19) Dashboard." 2020. https://covid19.who.int/. 1182 -----. 2021. "THE GLOBAL HEALTH OBSERVATORY." 2021. 1183 https://www.who.int/data/gho/data/themes/topics/indicator-groups/indicator-group-1184 details/GHO/sdg-target-3.c-health-workforce. 1185 "WHO | Rift Valley Fever - Gambia." 2018, February. http://www.who.int/csr/don/26-february-1186 2018-rift-valley-fever-gambia/en/. 1187 Wilson, M. L., L. E. Chapman, D. B. Hall, E. A. Dykstra, K. Ba, H. G. Zeller, M. Traore-1188 Lamizana, J. P. Hervy, K. J. Linthicum, and C. J. Peters. 1994. "Rift Valley Fever in 1189 Rural Northern Senegal: Human Risk Factors and Potential Vectors." The American 1190 Journal of Tropical Medicine and Hygiene 50 (6): 663–75. 1191 Woods, Christopher W., Adam M. Karpati, Thomas Grein, Noel McCarthy, Peter Gaturuku, Eric 1192 Muchiri, Lee Dunster, et al. 2002. "An Outbreak of Rift Valley Fever in Northeastern 1193 Kenya, 1997-98." Emerging Infectious Diseases 8 (2): 138. 1194 Yen, Catherine, Terri B. Hyde, Alejandro J. Costa, Katya Fernandez, John S. Tam, Stéphane 1195 Hugonnet, Anne M. Huvos, Philippe Duclos, Vance J. Dietz, and Brenton T. Burkholder. 1196 2015. "The Development of Global Vaccine Stockpiles." The Lancet Infectious Diseases 1197 15 (3): 340-47. 1198 Yob, J. M., H. Field, A. M. Rashdi, C. Morrissy, B. van der Heide, P. Rota, A. bin Adzhar, et al. 1199 2001. "Nipah Virus Infection in Bats (Order Chiroptera) in Peninsular Malaysia." 1200 Emerging Infectious Diseases 7 (3): 439–41. 1201 Youssouf, Hassani, Marion Subiros, Genevieve Dennetiere, Louis Collet, Laure Dommergues, 1202 Amandine Pauvert, Patrick Rabarison, et al. 2020. "Rift Valley Fever Outbreak, Mayotte, 1203 France, 2018–2019." Emerging Infectious Diseases 26 (4): 769. 1204

1205	Supplementary Information	
1206		
1207	Table of Contents	
1208		
1209	Table S1	35
1210	Figures S1-S4	
1211	SI Text	40
1212	1. Sensitivity analysis: Reactive vaccination strategies	40
1213	2. Sensitivity analysis: R ₀	41
1214	3. Model limitations	41
1215	Figures S5-S34	45
	-	

Parameter	LASV	MERS-CoV	NiV	RVFV
Case reports	1-11	11-15	11,16-22	11,23-43
Seasonality	See case reports	See case reports	See case reports	See case reports
Incubation period	44-47	48-51	52	53-60
Infectious period	47	48,51,61,62	63	64
R₀	65	49, 66-70	52	

1216 Table S1. Overview of data references.

1217 1 ("Nigeria Centre for Disease Control" n.d.), 2 (Carey et al. 1972), 3 (Monath et al. 1973), 4 (Bowen et al. 1218 1975), 5 (E Keane 1977), 6 (ter Meulen et al. 2001), 7 (Aiavi 2013), 8 (Fisher-Hoch et al. 1995), 9 (Fraser 1219 et al. 1974), 10 (Hamblion et al. 2018), 11 (ProMED-mail 2020), 12 ("MERS-CoV Cases" n.d.), 13 1220 ("Ministry of Health - Kingdom of Saudi Arabia" 2020), 14 (Reeves, Samy, and Townsend Peterson 1221 2015), 15 http://rambaut.github.io/MERS-Tools/cases2.html, 16 (Hsu et al. 2004), 17 (Gurley, 1222 Montgomery, Hossain, Islam, et al. 2007), 18 (Kumar et al. 2019), 19 (Nikolay, Salje, Hossain, Khan, 1223 Sazzad, Rahman, Daszak, Ströher, Pulliam, Kilpatrick, Nichol, et al. 2019), 20 (Tan, Tan, and Goh 1999), 1224 21 (Parashar et al. 2000), 22 (Chan et al. 2002a), 23 ("Rift Valley Fever in Egypt and Other African 1225 Countries: Historical Review, Recent Outbreaks and Possibility of Disease Occurrence in Egypt" 2018), 1226 24 (Laughlin et al. 1979), 25 ("WHO | Rift Valley Fever – Gambia" 2018), 26 (Centers for Disease Control 1227 and Prevention (CDC) 1998), 27 (Woods et al. 2002), 28 (Centers for Disease Control and Prevention 1228 (CDC) 2007), 29 (Jouan et al. 1988), 30 (Faye et al. 2007), 21 (Sow et al. 2014), 32 (Bob et al. 2017), 33 1229 (Sissoko et al. 2009), 34 (Métras et al. 2016), 35 (Youssouf et al. 2020), 36 (Centers for Disease Control 1230 and Prevention (CDC) 2020), 37 (FAO 2017), 38 (Ahmad 2000), 39 (Sow et al. 2016), 40 (Centers for 1231 Disease Control and Prevention (CDC) 1998), 41 (Nderitu et al. 2010), 42 (WHO 2018), 43 (Archer et al. 1232 2013), 44 (Frame et al. 1970), 45 (Monath 1974), 46 (Mylne et al. 2015), 47 (Khan et al. 2008), 48 (Assiri, 1233 Al-Tawfiq, et al. 2013), 49 (Cauchemez et al. 2014), 50 (Virlogeux et al. 2016), 51 (Sha et al. 2017), 52 1234 (Nikolay, Salje, Hossain, Khan, Sazzad, Rahman, Daszak, Ströher, Pulliam, Kilpatrick, Nichol, et al. 1235 2019), 53 (Daubney, Hudson, and Garnham 1931), 54 (Francis and Magill 1935), 55 (Kitchen 1934), 56 1236 (Findlay 1932), 57 (Sabin and Blumberg 1947), 58 (Smithburn and Mahaffy 1949), 59 (Mundel and Gear 1237 1951), 60 (Hoogstraal et al. 1979), 61 (Ki 2015), 62 (Park et al. 2016), 63 (Gurley, Montgomery, Hossain, 1238 Bell, et al. 2007), 64 (Bird et al. 2009), 65 (Lo lacono et al. 2015), 66 (Breban, Riou, and Fontanet 2013), 1239 67 (Poletto et al. 2014), 68 (Chowell et al. 2014), 69 (Kucharski and Althaus 2015), 70 (Cauchemez et al. 1240 2016) 1241 1242

1242 1243

1244

1245



Figure S1. Spillover and reactive vaccination patterns for Lassa fever virus (LASV). (A)
 Observed weekly Lassa fever spillover cases (grey bars) and estimated seasonal spillover rate
 (red line). (B) Annual number of spillovers over the past 5 years (red) and cumulative

(red line). (B) Annual number of spillovers over the past 5 years (red) and cumulative
distribution of simulated annual spillovers from 1000 replicates (grey). (C) Median weekly

1252 simulated spillover and human-to-human Lassa fever cases. (D) Average weekly number of

1253 reactive campaigns triggered via spillover detection compared to the estimated seasonal

1254 spillover rate (red line).


Figure S2. Spillover and reactive vaccination patterns for Middle Eastern respiratory virus (MERS-CoV). (A) Observed weekly MERS spillover cases (grey bars) and estimated seasonal spillover rate (red line). (B) Annual number of spillovers over the past 5 years (red) and cumulative distribution of simulated annual spillovers from 1000 replicates (grey). (C) Median weekly simulated spillover and human-to-human MERS cases. (D) Average weekly number of reactive campaigns triggered via spillover detection compared to the estimated seasonal spillover rate (red line).



Figure S3. Spillover and reactive vaccination patterns for Nipah virus (NiV). (A) Observed weekly Nipah spillover cases (grey bars) and estimated seasonal spillover rate (red line). (B) Annual number of spillovers over the past 5 years (red) and cumulative distribution of simulated annual spillovers from 1000 replicates (grey). (C) Median weekly simulated spillover and human-to-human Nipah cases. (D) Average weekly number of reactive campaigns triggered via spillover detection compared to the estimated seasonal spillover rate (red line).





- 1273 past 5 years (red) and cumulative distribution of simulated annual spillovers from 1000
- 1274 replicates (grey). (C) Median weekly simulated spillover and human-to-human RVF cases. (D)
- 1275 Average weekly number of reactive campaigns triggered via spillover detection. Fitted
- seasonality is not shown for RVFV as it was for the other pathogens because seasonality was fitseparately for each region.

1278 **SI Text**.

1279

1280 **1. Sensitivity analysis: Analysis of reactive vaccination scenarios**1281

1282 In addition to our baseline reactive vaccination scenario, we examined the sensitivity of 1283 vaccination impact to varying different scenario parameters: the threshold number of cases 1284 needed to trigger a response, vaccination coverage in the general population, vaccination 1285 coverage of healthcare workers (HCWs), time from the threshold trigger to the start of 1286 vaccination, vaccine per exposure protection for one or two doses (PEP), and time delay from 1287 vaccination to protection (see Table 2 for default, low, and high parameter values). In addition, 1288 we examined the sensitivity of model results to the assumed or estimated value of R_0 for each 1289 pathogen (SI Text section 2), and the impact of defining different catchment areas for 1290 vaccination (SI Text section 3). The results of the sensitivity analysis for MERS-CoV are 1291 summarized in the main text (Figure 6).

1292

1293 As expected, lowering the number of cases required to trigger a reactive vaccination campaign 1294 or increasing the percent of the population targeted for vaccination increased the number of 1295 vaccine regimens required for each pathogen (Figures S5-S8). These parameter values had a 1296 similar impact on the number of vaccine regimens needed to vaccinate HCWs (Figures S9-1297 S12). Higher R_0 values also increased the required number of vaccine regimens needed as 1298 higher human-to-human transmission increased the likelihood of the case threshold being 1299 exceeded. However, this impact was fairly small for LASV and RVFV due to their low R₀ values 1300 (Figures S5,S8).

1301

1302 When vaccination impact was measured as the fraction of cases averted, the largest impact for 1303 each pathogen was achieved by lowering the threshold number of cases needed to trigger a 1304 reactive vaccination campaign (Figures 4A, S13A-15A). The second largest impact on the 1305 fraction of cases averted for each pathogen besides RVFV was achieved by decreasing the 1306 delay between a campaign being triggered and the start of vaccination (Figures 4A, S13A-1307 S14A). For RVFV, the 2nd largest fraction of cases could be averted by increasing vaccination 1308 coverage in the general population or increasing vaccine PEP for a single dose vaccine (Figure 1309 S15A). Although lowering the response threshold maximized the fraction of cases averted for 1310 each pathogen, it did not maximize the number of cases averted per vaccine regimen 1311 administered, because lowering the threshold increased the number of vaccine campaigns and 1312 the required number of vaccine regimens (Figures S5-S8, 4B, S13B-S15B). For LASV, the 1313 largest per regimen impact was achieved by minimizing the delay prior to vaccination (Figure 1314 S13B). For NiV and RVFV, the largest per regimen impact was achieved by raising the 1315 response threshold (Figures S14B-S15B).

1316

For each pathogen (besides RVFV, which is not associated with nosocomial transmission)
 vaccinating HCWs had a larger per regimen impact than vaccinating the general population
 (Figures 40, S120, S140). Beducing the delay prior to vaccination and increasing vaccing DED

(Figures 4C, S13C-S14C). Reducing the delay prior to vaccination and increasing vaccine PEP
 had the largest impact on the number of cases averted per HCW vaccinated (Figures 4C, S13C-

1321 S14C). The number of cases averted was slightly lower under our high-coverage of HCWs

scenario because the high coverage of vaccination among HCWs was paired with low coverage
among the general population (Figures 4A, S13A-S15A). However, this scenario would have
achieved the highest number of cases averted per total number of vaccine regimens
administered for LASV, MERS-CoV, and NiV.

1326

1327 2. Sensitivity analysis: Impact of R₀

1328

1329 All R_0 values and uncertainty ranges used in our analysis were either drawn from the literature 1330 or estimated from data (see Table 1 for parameter values and data sources). However, R₀ 1331 estimates vary between studies and can also vary in space or time due to different 1332 environmental conditions or differences in human contact networks. Therefore, we also tested 1333 the sensitivity of our model results to lower and higher R_0 values for each pathogen (for RVFV, 1334 the default $R_0=0$, so only sensitivity to a higher value was examined). The number of total cases 1335 increased with R₀ for each pathogen, with the largest sensitivity observed for MERS-CoV 1336 because the high estimate of R_0 was close to 1 (Figure S16). There was also a large increase in 1337 the number of vaccine regimens required to vaccinate either the general population or HCWs for 1338 MERS-CoV at the higher R_0 value, but the impact of R_0 on the required number of vaccine 1339 regimens was minimal for the other pathogens (Figures S17-S18). As a result, there were 1340 minimal differences in the impact of vaccination under higher or lower R₀ values for LASV, NiV, 1341 or RVFV (Figures S19-S22). Vaccination averted both a greater magnitude and a higher fraction 1342 of MERS cases as R₀ increased (Figures S19-S20). In addition, the number of MERS cases 1343 averted per vaccine regimen administered to the general population or to HCWs also increased 1344 as R₀ increased (Figures S21-S22). These results highlight the increasing potential 1345 effectiveness for reactive vaccination as a control strategy as R_0 approaches 1 and larger 1346 outbreaks become more likely.

1347

1348 3. Model limitations

1349

1350 The goal of our analysis was to estimate vaccine stockpile needs and identify the most 1351 important determinants of success for reactive vaccination of zoonotic emerging pathogens. We 1352 modeled several different reactive vaccination strategies that are applicable to any zoonotic 1353 emerging pathogen, and tested this framework for four pathogens with differing epidemiologies. 1354 In addition, we explored the sensitivity of our results to different aspects of reactive vaccine 1355 deployment, such as the coverage level, deployment delays, and vaccine per exposure 1356 protection. However, there are some limitations to our approach that could affect these 1357 estimates.

1358

First, we have a relatively poor understanding of the epidemiology of most emerging zoonotic pathogens, and data that could be used to try and elucidate the most important aspects of their epidemiologies is limited. Here we examined the impact of reactive vaccination for four pathogens with differing epidemiologies to try and capture how a range of epidemiological parameters (e.g., spillover rates, R₀, etc.) affect vaccine stockpile requirements and the likely impact of vaccination. But there are still uncertainties surrounding the epidemiology of these pathogens that could affect the results of our analysis, such as the frequency of human-to-

1366 human transmission of MERS-CoV in community settings (Group and The WHO MERS-CoV 1367 Research Group 2013), or the route of NiV spillover to humans during recent outbreaks in India 1368 (Arunkumar et al. 2019). In addition, because no vaccines have been licensed for these 1369 pathogens yet, we had to make assumptions about key vaccine parameters (e.g., number of 1370 doses, time between vaccination and protection, and per exposure protection), based on the 1371 current vaccine target product profiles (TPPs) for each pathogen. We also had to make 1372 assumptions about the baseline reactive vaccination campaign parameter estimates such as 1373 campaign response time and duration (and best-case and worst-case scenarios for our 1374 sensitivity analysis). Assessing vaccine stockpile needs for newly emerged pathogens will 1375 involve even more uncertainty as epidemiological knowledge is critically limited immediately 1376 following emergence, as was demonstrated following the 2019 emergence of SARS-CoV-2 (Lee 1377 et al. 2020; Tindale et al. 2020). Our modeling approach can be applied to newly emerged 1378 zoonotic pathogens, but there will likely be a large amount of uncertainty regarding vaccine 1379 stockpile needs and where vaccination campaigns are most likely to occur. 1380

A second, related, limitation, is that the modeling framework is intended to be applicable for a
range of emerging zoonotic pathogens, and therefore cannot incorporate all of the specific
epidemiological details that might affect vaccine demand or impact for a particular pathogen.

1384

1385 Third, we only considered reported cases when estimating pathogen spillover rates and human-1386 to-human transmission because undiagnosed or unreported infections would not trigger an 1387 outbreak response. For several of the pathogens considered, however, the majority of 1388 infections--and even symptomatic cases--go unreported. A frequently cited study estimated that 1389 LASV infects 100,000-300,000 and kills 5,000 people annually (McCormick et al. 1987), and 1390 seroprevalence studies in several endemic areas indicate that spillover occurs much more 1391 frequently than reported (Kernéis et al. 2009; O'Hearn et al. 2016; Gibb et al. 2017). 1392 Seroprevalence surveys for RVFV and MERS-CoV also indicate that these pathogens cause 1393 many unreported infections in at least some subpopulations (Müller et al. 2015; Munyua et al. 1394 2021; Bron et al. 2021). Therefore, our estimate of reactive vaccination impact does not take 1395 into account the potential reduction in unobserved cases that would occur if at-risk populations 1396 were vaccinated. Improved surveillance could address this issue and would likely increase the 1397 frequency of reactive vaccination campaigns. This detection issue could also be partially 1398 addressed by adjusting the case threshold for outbreak response to account for the case 1399 detection probability, and then also adjusting vaccination impact to account for undetected 1400 infections.

1401

Next, because the extent of community transmission for each of the study pathogens is poorly
understood, we assumed that human-to-human transmission was limited to nosocomial
settings. Although this could result in an underestimate of vaccine demand, our model
simulations are consistent with epidemiological patterns observed to date (Figures S1-S4). We
also assumed that all nosocomial transmission involved transmission from patient to HCWs or
between HCWs and that there was no patient-to-patient or HCW-to-patient transmission.
Therefore our estimates of the impact of vaccinating HCWs represents the upper-bound on the

effectiveness of this strategy as instances of patient-to-patient transmission would not beprevented via this strategy.

1411

1412 Another simplifying assumption of our model is that cases in one catchment area do not lead to 1413 transmission or an outbreak outside of that catchment area. However, imported cases of these 1414 pathogens have been reported. A MERS-CoV outbreak in South Korea derived from a spillover 1415 event in the Middle East (Park et al. 2016), a NiV outbreak in Singapore derived from a spillover 1416 event in Malaysia (Chan et al. 2002b), and cases of Lassa fever have been imported to Europe 1417 (Overbosch et al. 2020). These types of events have been rare, and none of these documented 1418 events resulted in an outbreak larger than the range of those that we simulated. Furthermore, 1419 documented outbreaks involving pathogen spread to neighbouring catchment areas are 1420 included in our datasets, and as such are to some extent captured in the current analysis. For 1421 example, our datasets include Lassa fever cases in Benin derived from an outbreak in the 1422 neighbouring adm2 located in Nigeria and RVFV outbreaks within multiple catchment areas of 1423 Tanzania that likely resulted from the movement of livestock (ProMED-mail 2020: Bron et al. 1424 2021). Therefore, our model already implicitly incorporates the possibility of spread between-1425 catchment areas, and although our model does not predict spillover cases occurring outside of 1426 each pathogen's currently documented geographic distribution, the reactive vaccination 1427 strategies we examined should also be applicable for responding to imported cases and their 1428 associated outbreaks.

1429

1430 Another limitation is that we had to make several simplifying assumptions regarding the 1431 implementation of the reactive vaccination campaigns. One such simplification was assuming 1432 that all vaccine doses (per regimen) were administered on the same day. This is likely an 1433 unrealistic assumption for mass vaccination campaigns, particularly those that cover large 1434 geographic areas. Relaxing this assumption would reduce the public health impact of reactive 1435 vaccination in the same manner that delays in the start of the vaccination campaign did in our 1436 analysis. Another simplification is that we did not consider any targeted vaccination strategies 1437 besides targeting healthcare workers to limit nosocomial outbreaks or ring vaccination around 1438 index cases. For the ring vaccination we calculated the number of index cases that would trigger 1439 a ring vaccination response, but we did not model the impact of this response. Besides these 1440 two strategies, there might be other targeted vaccination approaches that would require a 1441 smaller vaccine stockpile than targeting the general population while still producing a substantial 1442 public health impact. For example, in the case of RVFV, a potential vaccination strategy might 1443 include targeting high-risk groups such as veterinarians, butchers, and livestock holders. One 1444 reason we did not consider this strategy is because of the coarseness or absence of the data 1445 available on these professions. While veterinarians only constitute a small proportion of the at-1446 risk population, their higher risk of acquiring infections could increase the impact of a campaign 1447 that targeted them for vaccination. This could also increase the safety of those that are often at 1448 the frontline of an outbreak response. Similar targeted strategies might be envisioned for camel 1449 workers in areas where MERS-CoV is endemic in livestock, or individuals who collect or 1450 consume date palm sap in India and Bangladesh (Dudas et al. 2018; Islam et al. 2016). 1451

1452 Finally, spillover cases were distributed over catchment areas representing 2nd administrative 1453 districts (or hospitals within the 1st administrative units in our sensitivity analysis), irrespective of 1454 the urban/rural nature of the catchment area. This may result in an overestimation of the 1455 population at risk and thus the number of regimens needed. Simulating the spillover rates per 2nd administrative unit, instead of at the 1st administrative level, could improve the estimation of 1456 reactive vaccine demand. However, the adm2 location of spillover cases were not available 1457 1458 most of the time. 1459 1460



1463 Figure S5. Vaccine regimens required for Lassa fever virus (LASV). The impact of varying

several model parameters on the number of vaccine regimens required to meet reactive

1465 vaccination campaign targets. Base refers to the default scenario used in our main analysis.

1466 See Table 2 for specific parameter values.

1467



- 1470 Figure S6. Vaccine regimens required for Middle Eastern respiratory virus (MERS-CoV).
- 1471 The impact of varying several model parameters on the number of vaccine regimens required to
- 1472 meet reactive vaccination campaign targets. Base refers to the default scenario used in our
- 1473 main analysis. See Table 2 for specific parameter values.





1476 **Figure S7. Vaccine regimens required for Nipah virus (NiV).** The impact of varying several

1477 model parameters on the number of vaccine regimens required to meet reactive vaccination

- campaign targets. Base refers to the default scenario used in our main analysis. See Table 2 for
- 1479 specific parameter values.



- 1481 Figure S8. Vaccine regimens required for Rift Valley fever virus (RVFV). The impact of
- 1482 varying several model parameters on the number of vaccine regimens required to meet reactive
- 1483 vaccination campaign targets. Base refers to the default scenario used in our main analysis.
- 1484 See Table 2 for specific parameter values.



1486 **Figure S9. Vaccine regimens required to vaccinate healthcare workers for Lassa fever**

1487 virus (LASV). The impact of varying several model parameters on the number of vaccine

1488 regimens required to meet reactive vaccination campaign targets among healthcare workers

- 1489 (HCWs). Base refers to the default scenario used in our main analysis. See Table 2 for specific
- 1490 parameter values.



- 1492 Figure S10. Vaccine regimens required to vaccinate healthcare workers for Middle
- 1493 **Eastern respiratory virus (MERS-CoV).** The impact of varying several model parameters on
- 1494 the number of vaccine regimens required to meet reactive vaccination campaign targets among
- 1495 healthcare workers (HCWs). Base refers to the default scenario used in our main analysis. See
- 1496 Table 2 for specific parameter values.



- 1498 Figure S11. Vaccine regimens required to vaccinate healthcare workers for Nipah virus
- 1499 (NiV). The impact of varying several model parameters on the number of vaccine regimens
- 1500 required to meet reactive vaccination campaign targets among healthcare workers (HCWs).
- 1501 Base refers to the default scenario used in our main analysis. See Table 2 for specific
- 1502 parameter values.



1504 Figure S12. Vaccine regimens required to vaccinate veterinarians for Rift Valley fever

1505 **virus (RVFV).** The impact of varying several model parameters on the number of vaccine

1506 regimens required to meet reactive vaccination campaign targets among veterinarians (HCWs).

1507 Base refers to the default scenario used in our main analysis. See Table 2 for specific

1508 parameter values.



Figure S13. Vaccination impact sensitivity analysis for LASV. Sensitivity of vaccination impact for LASV to variation in different campaign parameters expressed as (A) fraction of cases averted, (B) cases averted per 100,000 vaccinated in the general population, and (C)

1513 cases averted per 1,000 health care workers (HCWs) vaccinated.



Figure S14. Vaccination impact sensitivity analysis for NiV. Sensitivity of vaccination impact
for NiV to variation in different campaign parameters expressed as (A) fraction of cases averted,
(B) cases averted per 100,000 vaccinated in the general population, and (C) cases averted per
1,000 health care workers (HCWs) vaccinated.



Figure S15. Vaccination impact sensitivity analysis for RVFV. Sensitivity of vaccination impact for RVFV to variation in different campaign parameters expressed as (A) fraction of cases averted, (B) cases averted per 100,000 vaccinated in the general population, and (C) cases averted per 1,000 health care workers (HCWs) vaccinated.



1525 Figure S16. Number of cases under different R₀ assumptions.



1527 Figure S17. Number of vaccine regimens required under different R₀ assumptions.



Figure S18. Number of vaccine regimens required for healthcare workers (HCWs) under
 different R₀ assumptions.



1532 Figure S19. Number of cases averted by vaccinating the general population under

1533 different R₀ assumptions.



Figure S20. Fraction of cases averted by vaccinating the general population under
 different R₀ assumptions.

1557 **un**



Figure S21. Number of cases averted per vaccine regimen administered to the general
 population under different R₀ assumptions.



Figure S22. Number of cases averted per vaccine regimen administered to healthcare
 workers (HCWs) under different R₀ assumptions.

1546 **3. Analysis of different spillover and vaccination catchment areas**

1547

1548 In our analysis we estimated spillover rates for each pathogen at the 1st administrative level 1549 (adm1). We then accounted for spatial clustering of cases below the adm1 level by associating 1550 each simulated case with a catchment area. In the main analysis, catchment areas were defined 1551 as the 2nd administrative units (adm2) within each adm1. For countries with no 2nd 1552 administrative level, hospitals within an adm1 were treated as catchment areas (hospitals within 1553 10 km were combined into a single catchment area). This catchment area definition produced 1554 1570 catchment areas for LASV, 767 for MERS-CoV, 5076 for NiV and 2126 for RVFV. Here we 1555 consider two alternative catchment area definitions: (1) treating all adm1 units as unique 1556 catchment areas, and (2) treating all hospitals within adm1 units as unique catchment areas 1557 (with hospitals <10km apart combined into a single catchment area). The adm1 catchment area 1558 definition resulted in 214 catchment areas for LASV, 82 for MERS-CoV, 375 for NiV and 343 for RVFV. The adm1 hospitals catchment area definition produced 1749 catchment areas for 1559 1560 LASV, 3138 for MERS-CoV, 10799 for NiV and 4722 for RVFV. Therefore the adm1 catchment 1561 areas are larger than the adm2 catchment areas, while the adm1 hospitals catchment areas are 1562 generally smaller than the adm2 catchment areas. Because spillover rates were estimated at 1563 the adm1 level, spillovers within an adm1 unit were allocated via a multinomial distribution to all 1564 hospital catchment areas within that adm1 unit, with a probability of 1/(# of catchment areas 1565 within adm1).

1566

The number of spillover cases remained the same under the different catchment area 1567 1568 definitions, but the frequency, timing, and location of reactive vaccination campaigns were 1569 shifted. Reactive vaccination campaigns tended to be triggered sooner during the transmission 1570 season for adm1 catchment areas because these catchment areas covered a broader area and 1571 larger population (Figures S23-S26). There were only minor differences in the timing of 1572 vaccination campaigns between the adm2 and adm1 hospitals catchment areas (Figures S1-S4, 1573 S27-S30). The geographic distribution of spillovers was less clustered for the larger adm1 1574 catchment areas, but more finely distributed and clustered for the adm1 hospital catchment 1575 areas, particularly in countries like South Africa and Madagascar with large 1st-level 1576 administrative regions (Figures 2A, S31A-S32A). A similar geographic pattern was observed for 1577 the location of reactive vaccination campaigns (Figures 2B, S31B-S32B).

1578

1579 The total number of human-to-human cases did not differ by catchment area definition for any of 1580 the pathogens (Figures 1A, S33A-S34A). The median number of reactive vaccination 1581 campaigns was lower using adm1 catchment areas than adm2 catchment areas for MERS-CoV 1582 (3; 95% Prl: 1-6 vs. 4; 95% Prl: 0-11) and RVFV (3; 95% Prl:0-6 vs. 5; 95% Prl: 0-20) (Figures 1583 1B, S33B). In contrast, the median number of reactive vaccination campaigns were higher using 1584 adm1 catchment areas for LASV (3; 95% Prl: 1-6 vs. 0; 95% Prl: 0-20) and NiV (1; 95% Prl: 0-3 1585 vs. 0; 95% Prl: 0-8). The frequency of years with no reactive vaccination campaigns was lower 1586 using adm1 catchment areas compared to adm2 or adm1 hospital catchment areas for all four 1587 pathogens. Both the median number of reactive vaccination campaigns and the frequency of 1588 years with no campaigns were similar using adm1 hospital catchment areas compared to the

baseline adm2 catchment areas, although the frequency of years with no campaigns was
slightly higher for the adm1 hospital catchment areas for all four pathogens (Figures 1B, 34B).

1592 The number of vaccine regimens required to cover the general population were significantly 1593 higher using adm1 catchment areas versus adm2 or adm1 hospital catchment areas for 1594 (Figures 1C, S33C-34C). For MERS-CoV, the median required number of regimens increased 1595 from 286,259 (95% Prl: 0-855,099) for adm1 hospital catchment areas, to 1,242,922 (95% Prl: 1596 0-4,062,010) for adm2 catchment areas, and 14,303,325 (95% Prl: 1,416,969) for adm1 1597 catchment areas. For LASV, the median required number of regimens increased from 0 (95% 1598 Prl: 0-4,452,966) for adm1 hospital catchment areas and 0 (95% Prl: 0-5,184,360) for adm2 1599 catchment areas, to 11,603,802 (95% Prl: 2,953,628-25,277,594) for adm1 catchment areas. 1600 The number of vaccine regimens needed to vaccinate healthcare workers (HCWs) was also 1601 lowest for adm1 hospital catchment areas and highest for adm1 catchment areas (Figures 1C, 1602 S33C-S34C).

1603

1604 The total number of cases averted via vaccination for each pathogen was also lowest using 1605 adm1 hospital catchment areas and highest using adm1 catchment areas (Figures 1D, S33D-1606 S34D). For MERS, the median number of cases averted increased from 2 (95% PrI: 0-60) for 1607 adm1 hospital catchment areas, to 6 (95% PrI: 0-83) for adm2 catchment areas, and 77 (95% 1608 PrI: 0-342) for adm1 catchment areas. For Lassa fever, the median number of cases averted 1609 increased from 0 (95% PrI: 0-306) for adm1 hospital catchment areas and 0 (95% PrI: 0-357) for 1610 adm2 catchment areas, to 101 (95% Prl: 3-771) for adm1 catchment areas. For RVF, the 1611 median number of cases averted increased from 29 (95% PrI: 0-3,525) for adm1 hospital 1612 catchment areas, to 43 (95% PrI: 0-5,826) for adm2 catchment areas, and 66 (95% PrI: 0-1613 2,451) for adm1 catchment areas. For Nipah, the median number of cases averted was 0 for 1614 each catchment area definition, but the mean was highest for adm1 catchment areas. The total 1615 number of cases averted via vaccination of HCWs was also lowest using adm1 hospital 1616 catchment areas and highest using adm1 catchment areas (Figures 1D, S33D-S34D). For 1617 example, for MERS, the median number of nosocomial cases averted increased from 1 (95% 1618 Prl: 0-60) for adm1 hospital catchment areas, to 4 (95% Prl: 0-77) for adm2 catchment areas, 1619 and 55 (95% Prl: 0-259) for adm1 catchment areas.

1620

1621 Although the number of cases averted via reactive vaccination was highest using adm1 1622 catchment areas, the number of cases averted per vaccine regimen administered was not 1623 necessarily the highest under this scenario because the number of regimens required was also 1624 higher using adm1 catchment areas. For MERS, the highest per regimen impact was achieved 1625 using adm1 hospital catchment areas where a median of 0.75 (95% Prl: 0-18.10) cases were 1626 averted per 100,000 vaccine regimens administered. In comparison, a median of 0.58 (95% PrI: 1627 0.02-2.58) cases were averted per 100,000 vaccine regimens administered in adm1 hospital 1628 catchment areas, and 0.49 (95% Prl: 0-5.21) cases were averted per 100,000 vaccine regimens 1629 administered in adm2 catchment areas. The highest per regimen impact for RVF was also 1630 achieved using adm1 hospital catchment areas, with a median of 3.18 cases averted per 1631 100,000 vaccine regimens administered versus 2.86 (95% Prl: 0-349.78) using adm2 catchment 1632 areas or 1.69 (95% PrI: 0-68.42) using adm1 catchment areas. For Lassa fever the per regimen

1633 impact was relatively consistent across different catchment areas, and for Nipah the median 1634 impact per 100,000 vaccine regimens administered was 0 for adm2 or adm1 hospital catchment 1635 areas and 0.01 (95% PrI: 0-11.17) for adm1 catchment areas. For MERS and Lassa fever, the 1636 largest impact of vaccinating HCWs as measured on a per-regimen-administered basis, was also achieved using adm1 hospital catchment areas. The per-regimen impact of vaccinating 1637 1638 HCWs was minimal for Nipah, just as it was for vaccinating the general population (although the 1639 estimated per-regimen impact of vaccinating HCWs was higher than the impact of vaccinating 1640 the general population). 1641



Figure S23. Spillover and reactive vaccination patterns for Lassa fever virus (LASV) within adm1 catchment areas. (A) Observed weekly Lassa fever spillover cases (grey bars) and estimated seasonal spillover rate (red line). (B) Annual number of spillovers over the past 5 years (red) and cumulative distribution of simulated annual spillovers from 1000 replicates (grey). (C) Median weekly simulated spillover and human-to-human Lassa fever cases. (D) Average weekly number of reactive campaigns triggered via spillover detection compared to the estimated seasonal spillover rate (red line).



Weeks since January 1

Weeks since January 1

Figure S24. Spillover and reactive vaccination patterns for Middle Eastern respiratory
virus (MERS-CoV) within adm1 catchment areas. (A) Observed weekly MERS spillover
cases (grey bars) and estimated seasonal spillover rate (red line). (B) Annual number of
spillovers over the past 5 years (red) and cumulative distribution of simulated annual spillovers
from 1000 replicates (grey). (C) Median weekly simulated spillover and human-to-human MERS
cases. (D) Average weekly number of reactive campaigns triggered via spillover detection
compared to the estimated seasonal spillover rate (red line).



Figure S25. Spillover and reactive vaccination patterns for Nipah virus (NiV) within adm1
catchment areas. (A) Observed weekly Nipah spillover cases (grey bars) and estimated
seasonal spillover rate (red line). (B) Annual number of spillovers over the past 5 years (red)
and cumulative distribution of simulated annual spillovers from 1000 replicates (grey). (C)
Median weekly simulated spillover and human-to-human Nipah cases. (D) Average weekly
number of reactive campaigns triggered via spillover detection compared to the estimated
seasonal spillover rate (red line).



Figure S26. Spillover and reactive vaccination patterns for Rift Valley fever virus (RVFV)
 within adm1 catchment areas. (A) Observed monthly RVF spillover cases by region. (B)
 Annual number of spillovers over the past 5 years (red) and cumulative distribution of simulated

- annual spillovers from 1000 replicates (grey). (C) Median weekly simulated spillover and
 human-to-human RVF cases. (D) Average weekly number of reactive campaigns triggered via
- 1675 spillover detection compared to the estimated seasonal spillover rate (red line).
- 1676



Figure S27. Spillover and reactive vaccination patterns for Lassa fever virus (LASV)
within adm1 hospital catchment areas. (A) Observed weekly Lassa fever spillover cases
(grey bars) and estimated seasonal spillover rate (red line). (B) Annual number of spillovers
over the past 5 years (red) and cumulative distribution of simulated annual spillovers from 1000
replicates (grey). (C) Median weekly simulated spillover and human-to-human Lassa fever
cases. (D) Average weekly number of reactive campaigns triggered via spillover detection
compared to the estimated seasonal spillover rate (red line).



Weeks since January 1

Weeks since January 1

Figure S28. Spillover and reactive vaccination patterns for Middle Eastern respiratory virus (MERS-CoV) within adm1 hospital catchment areas. (A) Observed weekly MERS spillover cases (grey bars) and estimated seasonal spillover rate (red line). (B) Annual number of spillovers over the past 5 years (red) and cumulative distribution of simulated annual spillovers from 1000 replicates (grey). (C) Median weekly simulated spillover and human-tohuman MERS cases. (D) Average weekly number of reactive campaigns triggered via spillover detection compared to the estimated seasonal spillover rate (red line).



Figure S29. Spillover and reactive vaccination patterns for Nipah virus (NiV) within adm1 hospital catchment areas. (A) Observed weekly Nipah spillover cases (grey bars) and estimated seasonal spillover rate (red line). (B) Annual number of spillovers over the past 5 years (red) and cumulative distribution of simulated annual spillovers from 1000 replicates (grey). (C) Median weekly simulated spillover and human-to-human Nipah cases. (D) Average weekly number of reactive campaigns triggered via spillover detection compared to the estimated seasonal spillover rate (red line).


Figure S30. Spillover and reactive vaccination patterns for Rift Valley fever virus (RVFV)
within adm1 hospital catchment areas. (A) Observed monthly RVF spillover cases by region.
(B) Annual number of spillovers over the past 5 years (red) and cumulative distribution of
simulated annual spillovers from 1000 replicates (grey). (C) Median weekly simulated spillover
and human-to-human RVF cases. (D) Average weekly number of reactive campaigns triggered
via spillover detection compared to the estimated seasonal spillover rate (red line).

1711



- 1714 Figure S31. Geographic distribution of spillover cases and reactive vaccination
- 1715 **campaigns for adm1 catchment areas.** (A) Geographic distribution of the expected annual
- 1716 number of spillover cases for each pathogen. (B) Probability that a campaign will be triggered.

medRxiv preprint doi: https://doi.org/10.1101/2021.11.09.21266135; this version posted December 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.



1719 Figure S32. Geographic distribution of spillover cases and reactive vaccination

1720 campaigns for adm1 hospital catchment areas. (A) Geographic distribution of the expected

1721 annual number of spillover cases for each pathogen. (B) Proportion of time a campaign will be

1722 triggered.





(A) Annual number of spillover, human-to-human (H2H), and total cases for each pathogen
across the entire study region. (B) Annual number of vaccine campaigns that will be triggered
due to the outbreak threshold. (C) Number of vaccine regimens required per year for outbreak

1728 response when either the general population or healthcare workers (HCWs) only are targeted.

- 1729 (D) Annual number of cases averted via vaccination.
- 1730





catchment areas. (A) Annual number of spillover, human-to-human (H2H), and total cases for
 each pathogen across the entire study region. (B) Annual number of vaccine campaigns that will

1735 be triggered due to the outbreak threshold. (C) Number of vaccine regimens required per year

1736 for outbreak response when either the general population or healthcare workers (HCWs) only

1737 are targeted. (D) Annual number of cases averted via vaccination.